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SUMMARY 
Herpes simplex virus-1 (HSV-1) is one of the most common infectious agents found in 
humans, although only about a third of infected individuals exhibit symptoms such as cold sores and 
facial lesions. Its enveloped virions contain a 152 kilobases (kb) linear, double stranded (ds) DNA 
genome. HSV-1 replicates profusely in epithelial cells but in neurons, enters into latency, from which 
it can be reactivated to lytic replication by different external cues. The mechanism by which HSV-1 
switches between these two life cycle modes is not known. An understanding of this will not only 
improve understanding of viral physiology but also enhance development of improved tools for viral 
vector-mediated gene therapy. During productive replication HSV-1 synthesizes approximately 75 
proteins out of which five are translated immediately after infection. These are the immediate early 
(IE) proteins known as ICP0, ICP4, ICP22, ICP27 and ICP47 (ICP = infected cell protein). ICP0 is 
the first translated viral product and possesses multiple functions for the efficient progression of 
productive lytic infection. This thesis aimed to contribute to the understanding of the HSV-1 lytic-
latent transition by testing if artificial control over ICP0 transcription can be used to regulate HSV-1 
replication. 
The ICP0 gene is duplicated in the HSV-1 genome; the internal repeat (IR) and terminal 
repeat (TR) regions each encode one copy. In the present study, I removed one copy of ICP0 by 
deleting the IR region after which components of the Tetracycline-inducible system were inserted into 
the remaining copy to impose artificial transcriptional control of the gene. The IR-deleted mutant 
constructed using BAC technology confirms that the IR deletion does not affect viral replication in 
Vero cells. My results also indicate that the remaining copy of the ICP0 gene in TR becomes a critical 
determinant of productive infection when a second gene in this repeat, that of ICP34.5, is additionally 
deleted. My study further investigates the ability to regulate viral replication through the consensus 
TAATGARAT element which has a key role in ICP0 promoter function and reports that distal 
displacement of the TAATGARAT element away from its natural position diminishes immediate-
early ICP0 expression but results in surprisingly high late protein accumulation, altered protein 
cleavage and cytoplasmic translocation, all of which result in impaired viral growth. These defects 
could be reduced by repositioning the TAATGARAT motif to decrease the displacement but not by 
binding of tetracycline-responsive regulators to the artificially inserted tetO sites. The results further 
suggest that the HSV-1 proteins ICP0 and ICP4 can interfere with the tetracycline-responsive system 
and thereby disrupt the regulation. The study in this thesis supports the role of ICP0 as a critical 
switch component in HSV-1 productive infection but shows that high levels of ICP0 do not 
necessarily assure viral growth and may even be detrimental when expression kinetics are altered. Not 
only simulatory, but also inhibitory effects are mediated by the ICP0 promoter TAATGARAT 
element to impose complex dynamic control on ICP0 expression, and this cannot be reproduced by 
simply tethering VP16 to the promoter such as with the tetracycline-responsive system. Most 
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importantly, the present study indicates that: (1) simple ON and OFF switching of ICP0 transcription 
does not result in efficient viral replication which is dependent on correct ICP0 kinetics and (2) the 
tetracycline-responsive system may not accurately control ICP0 transcription due to interference by 
the ICP0 protein itself. 
 
 
 
 
 
 
Presentación 
 
PRESENTACIÓN 
El virus herpes simplex tipo I (VHS-1) es uno de los agentes infecciosos más comunes en el 
hombre, aunque sólo producen síntomas leves, como erupciones labiales y lesiones faciales, en un 
tercio de la población infectada. La estructura del virión está caracterizada principalmente por un 
genoma de DNA bicatenario lineal de 152 kilobases, y una envuelta lipídica. Tras la infección, en una 
primera fase lítica, el VHS-1 replica en células epiteliales hasta alcanzar las neuronas, donde establece 
un estado de latencia del que puede ser reactivado por diferentes estímulos externos. Dicho 
mecanismo de reactivación, a día de hoy desconocido, se propone como la clave no solo para 
esclarecer la fisiología del VHS-1 sino  para el desarrollo de futuras herramientas, basadas en vectores 
virales, para terapia génica. Durante su replicación productiva, el VHS-1 sintetiza aproximadamente 
75 proteínas, cinco de cuales son traducidas inmediatamente después de la infección. Dichas 
proteínas, denominadas proteínas inmediatamente tempranas (IE), son ICP4, ICP22, ICP27, ICP47 y 
ICP0 (ICP= acrónimo en inglés que significa “proteínas de célula infectadas”); ésta última es el 
primer producto viral traducido tras la infección y está dotada de múltiples funciones clave para el 
progreso eficiente de la  fase lítica de la infección. El objetivo general de la tesis aquí presentada ha 
sido intentar esclarecer el mecanismo de inactivación y reactivación del VHS-1 mediante  el control 
artificial de la transcripción de ICP0 y su posible utilidad para la regulación de la replicación viral.  
El gen de ICP0 se encuentra duplicado en el genoma del VHS-1, estando una de las copias 
codificada por la repetición interna del genoma viral (IR) y la otra por la repetición terminal (TR). En 
este estudio se ha deleccionado la IR, eliminando así la copia del gen de ICP0 presente en ésta, y  se 
ha insertado un sistema inducible por tetraciclina para posibilitar un control artificial de la 
transcripción de la copia de ICP0 de la región TR. De esta manera se generó el mutante de delección 
en la IR mediante el uso de la tecnología BAC (acrónimo en inglés que significa “cromasoma 
bacteriano artificial”), confirmando que la ausencia de esta copia de ICP0 no afecta la replicación 
viral en células Vero. En dicho mutante se observó que la copia restante del gen de ICP0 en IR 
adquiere un papel determinante en la infección viral productiva cuando también se delecciona 
ICP34.5, presente en IR. Así mismo, este estudio investiga la capacidad de regular la replicación viral 
a través del elemento consenso “TAATGARAT”, el cual posee una función clave en el promotor de 
ICP0, y pone de manifiesto que el desplazamiento de la posición del elemento TAATGARAT en el 
promotor disminuye la expresión inmediatamente temprana de ICP0; sin embargo, produce una 
sorprendente acumulación tardía de la proteína. Además se observa también un procesamiento 
proteico alterado así como una translocación citoplasmática, todo ello dando lugar a una disminución 
de la replicación viral. Dichos efectos se pueden revertir, al menos parcialmente, disminuyendo la 
distancia del desplazamiento de la posición del elemento “TAATGARAT”;  sin embargo no se 
observa ninguna reversión como resultado de la unión de proteínas reguladoras inducibles por 
tetraciclina a los sitios tetO que se insertaron artificialmente. Por otra parte, los resultados sugieren 
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que las proteínas de VHS-1, ICP0 e ICP4, podrían  estar interfiriendo con los componentes  del 
promotor mínimo del sistema inducible por tetraciclina (tetO/CMV), bloqueando de este modo la 
regulación dependiente de tetraciclina. 
El estudio presentado en esta tesis pone de manifiesto el rol de ICP0 como un componente 
crítico para la regulación de la infección productiva del VHS-1; no obstante, se ha observado que 
niveles altos de dicha proteína no aseguran necesariamente la replicación viral, llegando incluso a 
actuar en detrimento de ésta cuando su cinética de expresión se encuentra alterada. El elemento 
“TAATGARAT” del promotor de ICP0 no sólo media efectos activadores sino también inhibitorios 
para imponer un control complejo y dinámico de la expresión de ICP0. Estas funciones no se pueden 
reproducir a través de la mera unión de VP16 al promotor, como en el caso del sistema inducible por 
tetraciclina. 
En resumen, el estudio indica que: (1) un simple interruptor para la transcripción de ICP0 no 
es suficiente para una replicación viral eficiente, ya que depende de la correcta cinética  de expresión 
de ICP0, y (2) la expresión de ICP0 interfiere con la regulación de la transcripción del sistema 
inducible por tetraciclina. 
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1. INTRODUCTION 
Viruses have role in eukaryotic evolution by mediating horizontal gene transfer (reviewed in 
(Keeling & Palmer, 2008)). Researchers have utilized this property in developing viral vectors as a 
tool for highly efficient nucleic acid delivery to specific cell types. Many vectors derived from viruses 
like lentiviruses, retroviruses, adenoviruses and adeno-associated viruses (AAV) have been generated 
for use in gene therapy (reviewed in (Robbins et al, 1998)). However, use of these vectors is often 
restricted due to low cargo capacity, possible genetic mutations due to integration into the infected 
cell genome, or possible elimination of the infected cells due to host immune responses. 
HSV-1 is among the largest DNA viruses investigated for gene transfer (reviewed in 
(Glorioso, 2014)) and has been engineered as a vector for application in gene therapy (reviewed in 
(Lim, 2013)). The advantageous properties of HSV-1 as a vector are (1) natural neurotropism, (2) 
ability to exist as an episome in host cells, (3) large transgene capacity (it can package up to 160 kb of 
DNA), (4) high infectivity and (5) persistence in neurons in a latent state. Due to its ability to replicate 
vigorously in dividing cells and establish latency in neurons, HSV-1 has been considered ideal for 
oncolytic virotherapy ((Yao et al, 2010), reviewed in (Varghese & Rabkin, 2002) (Everts & van der 
Poel, 2005)) and gene therapy for neurological diseases such as Parkinson’s and Alzheimer’s disease 
((Lilley & Coffin, 2003; Perez et al, 2004), reviewed in (Fink et al, 2000; Frampton et al, 2005; 
Marconi et al, 2010)). In addition, the ability of HSV-1 to efficiently infect a number of different cell 
types, such as muscle and liver, make it an excellent vector for treating non-neurological diseases. 
However, one of the drawbacks of HSV-1 vectors has been its complexity due to the large size of its 
genome. HSV-1 vector engineering has greatly advanced recently due to the availability of complete 
viral genome sequences and bacterial artificial chromosome (BAC) clones of some widely-used 
laboratory HSV-1 strains (Gierasch et al, 2006; Saeki et al, 1998; Tanaka et al, 2003) together with 
molecular tools such as mutagenesis by homologous recombination (Zhang et al, 1998) and Cre 
recombinase-mediated BAC retrofitting (Kim et al, 1998). 
The ability of HSV-1 to switch between lytic infection and latency is an attractive property to 
exploit for HSV-1 vector engineering. On the one hand, efficient lytic growth in producer cells is 
required to generate high titers of vectors, while a latent-like state of the viral genome is desirable in 
target cells to ensure that the vector is transparent to the host. Although intensely investigated, the 
mechanisms by which the virus establishes and maintains latency or is reactivated into lytic 
replication are still not well understood. Knowledge of how HSV-1 switches between these two states 
will help not only in understanding the basic physiology of this virus but can also be applied to 
development of vectors as therapeutic tools. This understanding will also be helpful in the generation 
of easy-to-use packaging systems capable of producing high-titer homogeneous HSV-1 vectors. 
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The present study analyses the possibility of controlling the lytic-latent transition by 
manipulating HSV-1 regulatory genes. 
1.1. Herpes Simplex Virus-1 (HSV-1) 
HSV-1 (Lowenstein, 1919) belongs to Herpesviridae; a family of double stranded (ds) DNA 
viruses. The family name originates from the ancient Greek word “Herpein” meaning “to crawl” or 
“to creep”, to describe spreading lesions and recurrent infections. Until now, around 90 viral species 
have been identified for Herpesviridae, which appear to be ubiquitous in the animal kingdom. The 
members of the Herpesviridae family are characterized by large genome size (up to 250 kilobases 
(kb)), wide host range and the ability to enter into a latent state in specific cell types (reviewed in 
(Roizmann et al, 1992)). The family has been further classified into three subfamilies: 
Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae, based on their speed of replication, 
the cell type harboring latent virus and genomic analysis. HSV-1 belongs to the fast-growing, 
neurotropic Alphaherpesvirinae. 
1.1.1. HSV-1 involvement in diseases 
HSV-1 is ubiquitous in humans and on average 90% of the adult population is seropositive for 
anti-HSV-1 antibodies. Transmission of infection occurs either by direct mucosal contact or through 
abraded skin. HSV-1 is normally associated with oral, perioral, genital, skin and mucous membrane 
lesions. Recurrent HSV-1 infection in the eye may result in corneal scarring, sight threatening retinitis 
and blindness. Rarely, HSV-1 can spread to the central nervous system (CNS) and cause viral 
encephalitis (reviewed in (Liesegang, 2001)). Previous studies have pointed to a possible role of 
HSV-1 in Alzheimer’s disease (AD) (reviewed in (Itzhaki & Wozniak, 2008)) proposing that viral 
infection acts in combination with genetic factors to provoke accumulation of the AD hallmark 
proteins β-amyloid (Aβ) and abnormally phosphorylated tau (P-tau). A recent study has shown that 
with the use of anti-viral compounds the level of Aβ and P-tau decreases in HSV-1 infected Vero cells 
(Wozniak et al, 2011). 
1.1.2. Structure of the virion 
The HSV-1 virion is a sphere of approximately 180 nm diameter and possesses a dsDNA 
genome (reviewed in (Liesegang, 1992)). The morphological organization of the mature virion can be 
divided into four parts: (1) an electron dense core; containing a DNA genome of 152 kb and a 
molecular weight of approximately 100 x 10
6
 Dalton (Da) (Becker et al, 1968); (2) an icosahedral 
capsid; which protects the genome and consists of many viral proteins; (3) the tegument; an 
amorphous layer which surrounds the capsid and contains 20 different virus-encoded proteins with 
structural and regulatory roles; and (4) the envelope; an outer phospholipid bilayer. The intactness of 
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the envelope is an absolute requirement for the viability of the virion. The envelope is adorned with 
12-13 virally encoded glycoproteins which help the virus to interact with target cells (Figure 1A). 
 
Figure 1. Schematic representation of HSV-1 genome. 
A. Schematic representation of the mature HSV-1 virion consists of a dsDNA genome, an icosahedral capsid, 
the tegument and double layered envelope adorned with glycoprotein spikes. 
B. Schematic representation of the 152 kb long dsDNA genome of wild type HSV-1. The unique long (UL) and 
the unique short (US) segments are shown flanked by the internal repeat (IR) and the terminal repeat (TR). The 
unique origin of replication oriL is present in the UL segment (L enclosed by circle) and two copies of oriS (S 
enclosed by circle) are present flanking the US segment. Two packaging signals (a and a’) are present which are 
necessary for the packaging of the viral DNA into the virion. The 80 genes expressed in productive infection are 
indicated as essential or nonessential based on their requirement in vitro. Transcription of the viral genes occurs 
in three temporal phases after infection; immediate early (blue triangles), early (pink triangles) and late 
(turquoise triangles). The transcription stage of a few HSV-1 genes is not known and these are indicated as 
brown triangles. 
 
1.1.3. The HSV-1 genome 
The HSV-1 genome is a linear, 152 kb long dsDNA. It consists of: (1) two covalently linked 
unique fragments, one long (UL) and one short (Us) which comprise 82% and 18% of viral DNA 
respectively; (2) flanking repeated sequences, terminal repeat (TR) and internal repeat (IR) which 
encode immediate early regulatory proteins and a late protein ICP34.5; (3) three cis-acting origins of 
DNA replication, one in the middle of the UL region (oriL) and two flanking the US region (oriS); (4) 
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two packaging “a” sequences, one in the middle of the IR region and another at the end of the linear 
genome TR region (Figure 1B). The “a” sequences contain sites necessary for the packaging of viral 
DNA into the virion. The “a” sequence of the TR region is asymmetrically partitioned and consists of 
single base 3’ extensions. These serve as cohesive ends to circularize and generate an “endless” intact 
genome (Mocarski & Roizman, 1982) by homologous recombination mediated by cellular factors 
(reviewed in (Boehmer & Nimonkar, 2003)). An alternative mechanism for circularization, especially 
in light of the fact that certain herpesviruses lack terminal repeats, involves direct ligation of genomic 
termini. The covalently linked UL and US components can invert relative to each other to generate four 
genomic isoforms at equimolar levels (reviewed in (Roizman, 1979a; Roizman, 1979b)) which are all 
functionally equivalent and capable of independent replication (Jenkins & Roizman, 1986). 
Complete sequencing of the HSV-1 genome has been carried out on many different isolates 
(Macdonald et al, 2012a; Macdonald et al, 2012b; McGeoch et al, 1988; Norberg et al, 2011; Szpara 
et al, 2010) revealing that the virus encodes about 80 genes. Approximately half of the genes are 
dispensable for in vitro viral replication, but play significant roles in vivo in virus-host interactions 
(Figure 1B) (reviewed in (Nishiyama, 1996; Ward & Roizman, 1994)). 
1.1.4. Biology of HSV-1 
HSV-1 exhibits two modes of life cycle: Lytic and Latent. HSV-1 is highly replicative in 
rapidly dividing epithelial cells but establishes life-long latency in neuronal cell bodies following 
retrograde transport from nerve terminals (Kristensson et al, 1971). The lytic cycle of HSV-1 begins 
in epithelial cells of the skin or mucosa following attachment of the virion to the cell surface. HSV-1 
entry into target cells generally takes place either by fusion of the virion envelope with the plasma 
membrane or through endosomes. Depending on cell type, fusion can be pH-independent or may 
require low pH e.g HSV-1 entry into Vero cells is pH-independent (Koyama & Uchida, 1987) but 
requires a low pH for HeLa cells (Nicola et al, 2003). Viral entry is a complex process and involves 
interaction of multiple viral glycoproteins and cell surface receptors. Briefly, it takes place in two 
steps: (1) attachment of the viral particle to the cell surface, and (2) fusion of the viral envelope and 
plasma membrane. 
Of the 12 or more glycoproteins present on the HSV-1 viral envelope, coordinated action of 
five glycoproteins: gC, gD, gB and the heterodimer gH and gL, is required for viral entry into the 
target cell. gC and gB independently interact with cell surface heparan sulphate proteoglycan and 
mediate initial viral binding (Figure 2). In the absence of both gB and gC, virus binding to the cell 
surface is severely reduced (Herold et al, 1994). gD is the main receptor-binding glycoprotein and 
binds to three classes of cell receptor: (1) herpes viral entry mediator (HVEM); a member of the TNF 
receptor family; (2) nectin 1 and nectin 2; members of the immunoglobulin superfamily and (3) 3-O 
sulphated heparan sulphate ((Montgomery et al, 1996; Shukla et al, 1999) reviewed in (Spear et al, 
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2000)). The binding of gD to one of these receptors initiates the conformational changes mediated by 
gB, gD, gH, and gL and triggers the fusion between the virion envelope and the plasma membrane 
(Figure 2) ((Fuller & Lee, 1992), reviewed in (Connolly et al, 2011; Reske et al, 2007; Spear & 
Longnecker, 2003)). 
 
Figure 2. HSV-1 attachment and entry into the cell. 
Initial attachment of the HSV-1 particle to the host cell surface is mediated through binding of the envelope 
glycoproteins gC and/or gB to cell surface heparan sulphate (HS) proteoglycan. Binding of the virus to the cell 
surface is followed by attachment of the envelope glycoprotein gD to cell surface receptors herpes viral entry 
mediator (HVEM), nectin 1/2 or 3-O sulphated heparan sulphate (3-O-S HS) which initiates the conformational 
changes mediated by gB, gD, gH and gL leading to the fusion of viral envelope with the cell plasma membrane. 
 
After entry, the nucleocapsid is transported via the host’s cytoskeleton elements to the nuclear 
pores where the genome is then introduced into the nucleus. A viral tegument protein (UL 41) rapidly 
inhibits host protein synthesis and allows translation of viral transcripts by host ribosomes. Viral 
progeny of HSV-1 are produced by lytic replication. Virions which during the course of infection gain 
access to sensory nerve terminals undergo retrograde transport from the nerve endings in peripheral 
tissue to neuronal cell bodies deep in the spinal cord where HSV-1 establishes life-long latency 
(Figure 3) (reviewed in (Roizman & Whitley, 2013)). Periodic reactivation of the latent genome can 
occur spontaneously or in response to stimuli like ultraviolet (UV) light exposure, high temperature, 
fever, mental or physical trauma to the host, etc (Sawtell & Thompson, 1992; Wagner et al, 1975), 
bringing infectious viral progeny back to the nerve endings through anterograde transport, provoking 
skin lesions or mucosal ulcers (Figure 3) (reviewed in (Whitley et al, 1998)). 
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Figure 3. HSV-1 life cycle. 
HSV-1 entry into an epithelial cell is mediated through fusion of the viral envelope with the plasma membrane 
and release of the nucleocapsid and tegument into the cytoplasm. Transport of the nucleocapsid to the nucleus is 
mediated by the host cytoskeleton and the genome is injected into the nucleus through nuclear pores. Following 
lytic replication in the infected epithelia, progeny virions are retrogradely transported to the cell bodies of 
sensory neurons innervating the infection site. Upon arrival to the cell body, the virus either initiates lytic 
expression or enters latency. Periodic reactivation from latency can occur spontaneously or in response to a 
variety of stimuli, including stress to the cell, high temperature or ultraviolet light exposure, resulting in the 
production of progeny virions that are anterogradely transported back to the nerve terminal to infect new 
epithelial cells. 
 
1.1.5 HSV-1 lytic infection 
HSV-1 gene expression during lytic infection is tightly regulated. In lytic growth, the 80 odd 
genes are expressed and categorized in three sets on the basis of their requirements for expression: 
immediate early (IE) or α genes, early (E) or β genes and late (L) or γ genes. These three classes are 
expressed in a temporal cascade (Honess & Roizman, 1974). Expression of IE genes is independent of 
de novo viral protein synthesis but strongly stimulated by virion protein 16 (VP16), a component of 
the viral tegument (Gaffney et al, 1985). The synthesis of IE polypeptides reaches a peak between 2 to 
4 hours post infection (Honess & Roizman, 1974). IE genes transactivate early (E) gene transcription 
which results in the synthesis of E polypeptides with a peak of expression between 5 to 7 hours post 
infection (Honess & Roizman, 1974). E polypeptides include enzymes and viral DNA binding 
proteins necessary for replication. L genes are transcribed only after the completion of DNA 
replication and their expression is stimulated by the products of both earlier classes of genes (IE and 
E). The L polypeptides reach peak synthesis between 12 to 15 hours post infection (Honess & 
Roizman, 1974) and include the structural polypeptides of the virion. 
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Expression of IE genes is initiated by the tegument protein VP16 which is a 490 amino acid 
protein with a conserved core region and a C-terminal activation domain. The core of VP16 is divided 
into structured and unstructured regions (Liu et al, 1999). The structured region recognizes the 
TAATGARAT motif in DNA whereas the unstructured region interacts with cellular factors - octamer 
binding protein-1 (Oct-1) and host cell factor (HCF) to form the VP16 induced complex (VIC) 
(Figure 4) (reviewed in (Wysocka & Herr, 2003)). The formation of VIC facilitates the interaction of 
the activation domain of VP16 with host transcription factors and assists in the recruitment of host 
RNA polymerase II (RNA pol II) transcription machinery into the close proximity of IE promoters to 
initiate transcription (Gerster & Roeder, 1988; Klemm et al, 1995; O'Hare et al, 1988). 
 
Figure 4. The VP16 induced complex (VIC) 
VP16 has a C-terminal activation domain and transactivates transcription by binding to the TAATGARAT 
element (where R is a purine) present upstream of the TATA box in all IE gene promoters. VP16 forms a 
complex with the host cell factor (HCF) and localizes to the nucleus, where it binds to the host transcription 
factor octamer binding protein-1 (Oct-1) to form the VP16 induced complex (VIC). The binding of the VIC to 
the consensus TAATGARAT site enables the activator domain of VP16 to interact with host transcription 
factors and assist in the recruitment of the host RNA polymerase II transcription machinery into close proximity 
to IE promoters to initiate IE gene transcription. 
 
HSV-1 expresses five IE genes which are designated as infected cell polypeptides (ICPs): 
ICP4, ICP0, ICP22, ICP27 and ICP47 (Honess & Roizman, 1974). Figure 5 summarizes the 
regulation of the HSV-1 gene expression cascade during productive infection. 
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Figure 5. HSV-1 gene expression and regulation 
Schematic diagram depicting HSV-1 gene expression cascades during productive infection. VP16 interacts with 
Oct-1 and HCF to transactivate immediate early gene transcription. The immediate-early gene products 
stimulate early gene expression which encodes functions necessary for replication of the viral genome. Late 
genes are expressed after the commencement of DNA replication. Immediate-early gene products regulate the 
coordinated expression of the HSV-1 genome. ICP4 and ICP27 are necessary for viral replication and 
transactivate the expression of early and late genes. ICP0 is a promiscuous transactivator of viral genes and in 
synergy with ICP4 transactivates early and late genes. ICP4 is also a repressor of ICP0 and its own 
transcription. Although ICP22 is dispensable for viral replication in some cell types, it enables the optimal 
expression of late genes. 
 
1.1.5.1. ICP0 
ICP0 is a 775 amino acid multifunctional protein containing a RING (really interesting new 
gene) finger domain. It is the first translated product of HSV-1 after infection in a host cell and plays 
critical roles in overcoming host cell defenses, viral gene transactivation for efficient lytic replication, 
and reactivation from latency (Cai et al, 1993; Cai & Schaffer, 1992; Cai & Schaffer, 1989; Everett, 
1984; Harris et al, 1989; Kawaguchi et al, 1997; O'Hare & Hayward, 1985) (reviewed in (Everett, 
2000; Hagglund & Roizman, 2004)). The dependence of viral replication on ICP0 diminishes with 
increasing multiplicity of infection (MOI) and this IE protein is dispensable at high MOI (Everett, 
1989; Sacks & Schaffer, 1987; Stow & Stow, 1986). At low MOI in the absence of functional ICP0, 
cellular repressors silence HSV-1 mRNA synthesis, favoring the entry of the virus into latency 
(reviewed in (Everett, 2000)). ICP0 plays a central role in HSV-1 biology due to its multiple functions 
such as E3 ubiquitin ligase activity (Boutell et al, 2002), counteraction of host anti-viral (interferon) 
responses (Mossman et al, 2000; Mossman & Smiley, 2002), degradation of nuclear domain 10 
(ND10) bodies and inhibition of cellular repressors binding to the HSV-1 genome (Everett et al, 1998; 
Everett et al, 2008; Everett et al, 2006). 
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In the following sections I have briefly discussed ICP0 functions during HSV-1 infection to 
pose the question of whether manipulation of the gene encoding this protein can be a key to regulate 
HSV-1 lytic-latency balance. 
1.1.5.2. Functions of ICP0 
The HSV-1 genome possesses two copies of the ICP0 gene, present in the IR and the TR 
regions. The ICP0 gene is comprised of three exons encoding codons 1-19, 20-241 and 242-775 
respectively (Perry et al, 1986). 
 
Figure 6. The functional domains of ICP0 
The functional domains of ICP0 include the N-terminal RING finger motif (residues 116-156), regions of 
phosphorylation (Phos 1-3) (residues 224-232, residues 365-371, and residues 508-518), a C-terminal nuclear 
localizing signal (NLS) (residues 500-506), the Herpesvirus ubiquitin ligase (HUL) domain (residues 543-680), 
the ND10 localization domain (residues 633-767), a dimerization/multimerization motif (residues 617-711), the 
ubiquitin specific protease 7 (USP7) binding domain (residue 618-634) and the corepressor of repressor 
element-1 silencing transcription (CoREST) binding domain (residue 668-738). 
 
Functional domains have been mapped in ICP0 (Figure 6) which carry out the functions 
described in the following subsections. 
1.1.5.2.1. E3 ubiquitin ligase activity 
ICP0 exhibits E3 ubiquitin ligase activity and targets proteins for degradation. In concert with 
E2 ubiquitin enzyme, ICP0 interacts with components of the ubiquitin proteasome pathway and 
attaches polyubiquitin chains to target proteins in a RING-finger-dependent manner (reviewed in 
(Smith et al, 2011)). ICP0 targets include numerous cellular proteins such as DNA-dependent protein 
kinase, the PML (promyelocytic leukemia) protein in ND10 bodies, Sp100 (speckled protein of 100 
kDa), the DNA repair proteins RNF8 and RNF168, p53, and NF-κB (reviewed in (Smith et al, 2011)). 
The C-terminus of ICP0 consists of another ubiquitin ligase domain (residues 543-680) 
known as herpesvirus ubiquitin ligase 1 (HUL1) ((Hagglund & Roizman, 2002), reviewed in 
(Hagglund & Roizman, 2004)). The activity of this domain is independent of the RING finger domain 
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(Hagglund & Roizman, 2002; Hagglund & Roizman, 2003; Hagglund et al, 2002) and specifically 
targets degradation of the E2 ubiquitin-conjugating enzyme cdc34 (Van Sant et al, 2001). However, a 
later study indicated that HSV-1 infection did not alter cdc34 protein levels (Everett, 2004). So far, no 
other target protein has been identified for HUL1. 
The ICP0 orthologs of other herpesviruses like Bovine herpesvirus (BHV), Equine 
herpesvirus (EHV) and Varicella zoster virus (VZV) exhibit similar E3 ubiquitin ligase activity in 
vitro (Everett et al, 2010). 
1.1.5.2.2. HSV-1 gene transactivation 
ICP0 is a promiscuous transactivator of viral and non-viral genes in transient transfection and 
enhances viral replication both in vitro and in vivo (Cai & Schaffer, 1989; Everett, 1984; Everett, 
1985; Gelman & Silverstein, 1985; Harris et al, 1989; Kalamvoki & Roizman, 2010; Sacks & 
Schaffer, 1987). The transactivational property of ICP0 functions through the RING finger domain, 
mutation of which renders ICP0 defective (Chen & Silverstein, 1992). ICP0 transactivates all three 
classes of HSV-1 genes i.e. IE, E and L (Cai & Schaffer, 1992; Mavromara-Nazos et al, 1986) 
independently or in synergy with ICP4 (Everett, 1984; Gelman & Silverstein, 1986). ICP0 does not 
per se recruit transcription factors to the DNA but modifies chromatin to provide a suitable substrate 
for the transcription machinery (Kalamvoki & Roizman, 2010). 
1.1.5.2.3. Suppression of silencing of viral DNA 
An important contribution of ICP0 in productive infection is the suppression of host intrinsic 
and innate defense machinery to prevent silencing of the viral genome. ND10 bodies are small nuclear 
structures involved in cellular processes like proliferation and differentiation but also in intrinsic 
resistance against RNA and DNA viruses (reviewed in (Everett & Chelbi-Alix, 2007)). ICP0 inhibits 
ND10 bodies by colocalizing and degrading them in a RING finger dependent manner (reviewed in 
(Everett, 2001; Everett & Chelbi-Alix, 2007)). 
PML is an organizing protein of ND10 bodies. Previous studies have shown the potential role 
of PML in mediation of anti-viral functions (reviewed in (Regad & Chelbi-Alix, 2001)). A study on 
PML+/+ murine cells infected with an ICP0 mutant virus demonstrated profound inhibition of viral 
protein accumulation when treated with interferon (IFN)-alpha (α) or IFN-gamma (γ). The inhibition 
was higher when these IFNs were used in combination. However, similar experiments with wild type 
(WT) virus in PML+/+ cells or with the ICP0 mutant or WT virus in PML-/- cells showed minimal 
IFN inhibitory effect on viral protein accumulation (Chee et al, 2003), suggesting that the anti-HSV-1 
state induced by exogenous IFN is mediated by PML (Chee et al, 2003). ICP0 induces proteasome-
dependent degradation of PML, especially SUMOylated forms of the protein (Boutell et al, 2003; 
Everett et al, 1998; Muller & Dejean, 1999). An enhancement in growth and plaque formation was 
observed in the ICP0 null mutant when grown in a cell line artificially depleted for PML bodies 
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(Everett et al, 2008; Everett et al, 2006). The mechanism by which PML might act on intrinsic anti-
viral defense mechanisms is yet to be discovered but other relevant ICP0 targets involved are other 
ND10 components contributing to intrinsic resistance: Sp100, hDaxx (human death domain-
associated protein 6) and ATRX (alpha thalassemia/mental retardation syndrome X-linked) (Everett et 
al, 2008; Lukashchuk & Everett, 2010). 
1.1.5.2.4. Suppression of chromatinization of the viral genome 
Another model of cellular intrinsic resistance proposes rapid chromatinization of viral DNA 
upon infection by cellular histone proteins through the activities of histone deacetylase (HDAC) 
enzymes. To initiate IE transcription HSV-1 recruits lysine specific demethylase-1 (LSD-1) to the IE 
promoters to demethylate repressive histone protein H3 Lys9 (H3K9) (Liang et al, 2009). LSD-1 is a 
part of a cellular repressor complex which includes other components like histone deacetylase 1 
(HDAC1), histone deacytylase 2 (HDAC2), BRAF35 and corepressor of repressor element-1 
silencing transcription (CoREST). LSD-1 is stabilized by CoREST (Shi et al, 2005; Yang et al, 2006) 
which in turn needs repressor element-1 silencing transcription factor (REST) for stabilization. Knock 
down of REST or CoREST affects LSD-1 stability and availability for binding to the IE promoter, 
eventually affecting IE mRNA accumulation. LSD-1 mediated demethylation of histone proteins 
initiates viral IE transcription and translation. Translated ICP0 then binds to CoREST and displaces 
HDAC1 and HDAC2 from the repressor complex paving the way for E and L gene transcription 
(reviewed in (Roizman, 2011)). 
1.1.5.2.5. Counteraction of anti-viral response 
Interferons (IFNs) are cytokines with anti-viral and immunomodulatory functions (reviewed 
in (Le Page et al, 2000; Pestka et al, 1987; Sen, 2001)). IFN-α or IFN-beta (β) are secreted by cells as 
an innate response to viral infection whereas IFN-γ is an unrelated protein, produced almost 
exclusively by activated NK cells and T lymphocytes. IFNs activate IFN-stimulated genes (ISGs) 
which collectively function to inhibit viral replication and spread. ISGs can also be activated by viral 
infection in the absence of IFN (Wathelet et al, 1992) through interferon regulatory factors (IRFs); a 
family of transcription factors with broad range of functions (reviewed in (Mamane et al, 1999)). The 
role of ICP0 in counteraction of both IFN-dependent and -independent antiviral responses has been 
deduced from studies which show; (1) hypersensitivity of ICP0 mutants to IFN with decreased levels 
of viral mRNA transcripts and severely reduced plaque formation ability (Harle et al, 2002; Mossman 
et al, 2000); (2) enhancement in the growth of ICP0 mutants (up to 1000-fold) in IFN- α/β/γ null 
mutated mice (Leib et al, 1999) and (3) blocking of IRF3- and IRF7-mediated cellular responses by 
ICP0 RING finger dependent activity (Lin et al, 2004). 
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1.1.6. HSV-1 latency 
HSV-1 latency can be defined as retention of a complete viral genome as a non replicative 
episomal molecule in a host cell without production of any infectious virions (reviewed in (Efstathiou 
& Preston, 2005)). After productive infection, HSV-1 may contact sensory neurons innervating the 
site of primary infection and migrate to their neuronal cell bodies in trigeminal ganglia where the 
expression of all viral genes is repressed with the exception of latency associated transcripts (LATs) 
(Stevens et al, 1987), leading to the establishment of latency. Since its discovery in 1987 (Stevens et 
al, 1987) LATs have been constantly studied for their involvement in the lytic / latency / reactivation 
cycle of HSV-1. The general conclusion from this research is that LATs are not essential for latency 
establishment or maintenance, nor for reactivation to the lytic phase (reviewed in (Efstathiou & 
Preston, 2005)). Functional properties assigned to LATs are- (1) participation in establishment of 
latency; (2) protection of the host cell from virus-induced apoptosis; (3) modulation of viral IE gene 
expression; and (4) participation in mechanisms of in vivo virulence (reviewed in (David C. Bloom, 
2011)). 
HSV-1 can remain in a quiescent latent state in neurons throughout the lifespan of the host or 
may reactivate occasionally to the lytic form followed by anterograde transport to innervated 
peripheral sites (Figure 3) (reviewed in (Efstathiou & Preston, 2005)). The molecular events 
underlying the establishment and maintenance of HSV-1 latency are complex as host neurons can 
survive virus-induced cytopathic effects and maintain latency until reactivated due to external cues. 
1.1.6.1. Role of ICP0 in HSV-1 latency and reactivation 
The possible roles of ICP0 in viral latency come from previous studies where ICP0 mutants 
enter a quiescent state when infected at low MOI (Sacks & Schaffer, 1987; Stow & Stow, 1986). 
These mutant genomes can remain quiescent for many days and can be reactivated by superinfection 
with human cytomegalovirus (HCMV) or VZV (Stow & Stow, 1989). The reactivation function of 
ICP0 maps to exon 2 of ICP0 as mutants deleted for this region fail to reactivate (Harris et al, 1989). 
More detailed studies with ICP0 functional domains indicate involvement of the RING finger motif in 
removal of repressive chromatin and activation of quiescent genomes (Ferenczy et al, 2011). In an in 
vivo study Sawtell et al concluded that ICP0 is not essential as a component of the switch from 
latency to lytic-phase, but rather that it is critical in the initiation of the lytic cycle and production of 
infectious progeny once exit from latency has been accomplished (Thompson & Sawtell, 2006). In a 
recent study a neuron-specific host microRNA (miRNA) was identified which directly targets ICP0 to 
promote HSV-1 latency (Pan et al, 2014). 
Taken together, the above findings suggest that ICP0 plays critical roles in viral replication, 
latency and reactivation and therefore manipulation of ICP0 expression might be a key to switch 
HSV-1 between its two life modes: lytic replication and latency. 
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1.1.6.2. Other factors with a role in latency 
The HSV-1 mutant in1814 contains an insertion mutation in the coding sequence of VP16, 
impairing IE transactivation due to failure of the mutant VP16 protein to form a complex with cellular 
factors and the viral promoter element TAATGARAT. When used to infect non-complementing cells, 
the in1814 mutant enters a quiescent state in culture (Jamieson et al, 1995) and establishes latency in 
vivo (Steiner et al, 1990). The replication defect of in1814 can be partially overcome by expressing 
ICP0 in cells prior to the infection (Ace et al, 1989; Steiner et al, 1990). These observations have led 
to the hypothesis that the replication block in this mutant occurs before or at the IE gene expression 
stage. These studies indicate VP16 as an important contributor of viral replication, the absence of 
which pushes the mutant into a quiescent state. However, in one study Sears et al observed 
insignificant effects of VP16 on reactivation of a latent virus and concluded that lack of VP16 alone 
cannot account for latency establishment (Sears et al, 1991). 
1.2. Inducible systems for gene expression 
The ideal inducible system to regulate gene expression should include features such as: (1) 
tight regulation with no basal gene expression in the uninduced state; (2) high levels of gene 
expression in the presence of the inducer; (3) full reversibility of induction; (4) recapitulation of 
effects observed in vitro in models in vivo and (5) non-toxic and non-interfering inducers. 
Many inducible regulatory systems for mammalian gene expression have been developed, 
employing a variety of inducers such as heavy metals (Brinster et al, 1982; Mayo et al, 1982; Searle et 
al, 1985), steroid hormones (Hynes et al, 1981; Israel & Kaufman, 1989; Lee et al, 1981), heat shock 
(Wurm et al, 1986), antibiotics (Gossen & Bujard, 1992) and other small molecule ligands such as 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Baim et al, 1991). However, some of the above 
mentioned systems are unsuitable for certain applications due to inducer toxicity. Furthermore, 
undesirable pleiotropic effects have been observed in some cases. e.g. in the estrogen-based inducible 
system a chimeric molecule of the estrogen receptor dimerizes in response to the inducer estrogen and 
binds to galactose-responsive transcription factor 4 (GAL4)-responsive promoters, leading to the 
activation of target gene expression (Braselmann et al, 1993). A major drawback of this system is that 
endogenous genes containing similar sequence elements are also modulated. In addition, endogenous 
levels of estrogen may also activate basal transgene expression, resulting in “leakiness” of the system. 
1.2.1. Tetracycline-inducible system 
The tetracycline (Tet) inducible gene expression system in eukaryotes was first reported in 
plants. Gatz et al utilized the regulatory elements of the Tn10-specific tetracycline resistance operon 
from E. coli to construct an inducible system to regulate the transcription from tetracycline operator 
(tetO) sequences inserted into the cauliflower mosaic virus (CaMV) 35S promoter (Gatz et al, 1992; 
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Gatz & Quail, 1988). In mammalian systems, Tet regulated gene expression was first achieved in 
1992 by Bujard and co-workers to regulate the expression of the Photinus pyralis luciferase reporter 
gene (Gossen & Bujard, 1992). Kim et al in 1995 utilized this system to control β-glucuronidase gene 
(uidA) expression in a recombinant HCMV (Kim et al, 1995). Thereafter, many laboratories employed 
the Tet-inducible system to regulate gene expression in different viral vectors ((Corti et al, 1999; 
Haberman et al, 1998; Hofmann et al, 1996), reviewed in (Goverdhana et al, 2005)). 
The Tet system consists of: (1) a minimal promoter (in the original version, derived from the 
CMV IE promoter) juxtaposed to seven repeats of tetR binding sites (tetO) and (2) a transcriptional 
transactivator known as the tetracycline-responsive transactivator (tTA). tTA is a fusion protein of the 
transactivating domain of the HSV-1 VP16 protein and the DNA-binding domain of the tetracycline 
repressor (tetR) of E. coli (Gossen & Bujard, 1992; Gossen et al, 1995). In the absence of the 
antibiotic tetracycline or its analogue doxycycline, tTA binds to the tetO sites and activates the 
transcription of the transgene whereas in the presence of the same antibiotic, tTA dissociates from the 
tetO sites and transactivation of the transgene ceases, allowing control over transgene expression by 
presence or absence of antibiotic in the medium (Figure 7A). Since the tTA protein has been 
observed to be toxic to mammalian cells (reviewed in (Gossen et al, 1993)), an autoregulatory system 
for tTA expression was developed. The gene encoding for tTA was also placed under control of the 
Tet inducible system to make the expression of tTA itself inducible. This autoregulatory system was 
observed to improve inducibility of gene expression compared to the constitutively expressing tTA 
system, both in cultured cells and in animal models (Shockett et al, 1995). 
There are two basic variants of the Tet inducible expression system: the Tet-OFF system with 
tTA (Gossen & Bujard, 1992) and the Tet-ON system with reverse tetracycline responsive 
transactivator (rtTA) (Gossen et al, 1995). The rtTA protein differs from tTA by four amino acid 
changes in the original tetR domain. This mutation reverses the responsiveness of the rtTA protein to 
the inducer (tetracycline or doxycycline). In contrast to tTA, rtTA requires tetracycline/doxycycline 
for binding to tetO sites and is unable to bind in absence of tetracycline/doxycycline due to 
conformational changes (Figure 7B). In summary, Tet-OFF refers to a system where transgene is 
expressed in the absence of tetracycline/doxycycline whereas Tet-ON refers to a system where 
transgene is expressed in the presence of tetracycline/doxycycline. More recently, Urlinger et al have 
generated a novel mutant transactivator, rtTA2S-M2 which can regulate tetO controlled transgene 
expression with better inducibility and at tenfold less inducer concentration (Urlinger et al, 2000). 
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Figure 7. Regulation of gene expression 
by tetracycline transregulators. 
A. Tetracycline controlled transactivator 
(tTA) system: tTA is a fusion protein of the 
DNA-binding domain of the tetracycline 
repressor (tetR) of E. coli and the 
transcriptional activation domain of HSV-1 
virion protein 16 (VP16). In the absence of 
tetracycline, tTA binds to tetR binding sites 
in DNA (tetO) and activates transcription 
of the linked transgene. In the presence of 
tetracycline, tTA dissociates from tetO and 
terminates transcription of the transgene. 
B. Reverse tetracycline responsive 
transactivator (rtTA) system: rtTA is a 
mutant version of the transactivator tTA 
with four amino acid changes in the tetR 
domain. In the presence of tetracycline, 
rtTA binds to tetO sites and activates 
transcription of the linked transgene. In the 
absence of tetracycline, rtTA dissociates 
from tetO and transcription of the 
transgene is absent. 
C. Tetracycline responsive silencer protein 
(tTS) system; tTS is a fusion protein of 
tetR and transcriptional silencing domains 
of the Kid protein /or the Krüppel 
associated box (KRAB) domain of the 
human Kox1 zinc finger protein. In the 
absence of tetracycline, tTS binds to tetO  
sites and suppresses transcription of the linked transgene preventing leaky expression of the transgene. In the 
presence of tetracycline, tTS dissociates from tetO and transcriptional suppression of the transgene is absent. 
D. Reverse tetracycline responsive silencer protein (rtTS) system: rtTS is a mutant version of the transcriptional 
silencer tTS with four amino acid changes in the tetR domain. In the presence of tetracycline, rtTS binds to tetO 
sites and suppresses transcription of the linked transgene whereas in the absence of tetracycline, rtTS dissociates 
from tetO and transcriptional suppression of the target gene is absent. 
E and F. Combined use of Tetracycline transregulators (tTA, rtTS and rtTA, tTS). In the absence of tetracycline, 
rtTS dissociates from tetO whereas tTA binds tetO with high affinity and activates transcription and expression 
of the target gene. Response of the transcription with respect to the presence of tetracycline has been indicated 
on extreme right. This system is Tet-OFF, as the transcription of the transgene in this system occurs only in 
absence of tetracycline. In rtTA, tTS dual system, in the presence of tetracycline, tTS dissociates from tetO 
whereas rtTA binds tetO with high affinity and activates transcription and expression of the target gene. This is 
a Tet-ON system (as indicated on extreme right) as transcription of the transgene occurs only in the presence of 
the tetracycline. 
 
To address the problem of leaky basal gene expression in Tet inducible systems, Bujard and 
coworkers generated a Tet regulatory silencer protein tTSKid; a fusion of tetR repressor with the 
transcriptional silencing domain of the Kid protein (Freundlieb et al, 1999). In vitro studies 
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demonstrated that tTSKid suppresses basal expression levels by 1000-fold without affecting maximal 
induced expression of the reporter transgene (Freundlieb et al, 1999). Later, Lamartina et al 
constructed a bicistronic vector containing a single regulatory cassette co-expressing both activator 
(rtTA2S-M2) and repressor (tTSKid) elements by inclusion of an internal ribosome entry site (IRES) 
(Lamartina et al, 2003). In the absence of tetracycline/doxycycline, tTSKid binds to the tetO sites and 
results in negligible transgene expression whereas in the presence of tetracycline, tTSKid binding to 
tetO sites is replaced with rtTA2S-M2 which induces a 1000-fold increase in transgene expression 
(Lamartina et al, 2003). 
Another version of the Tet regulatory silencer was generated by Deuschle et al in which the 
Krüppel associated box (KRAB) domain of the human Kox1 zinc finger protein (Margolin et al, 
1994) was fused to the E. coli tetR protein to create the transcriptional repressor tetR-KRAB 
(Deuschle et al, 1995). In the absence of tetracycline/doxycycline, tetR-KRAB binds to the tetO sites 
and exerts its silencing activity, blocking the expression of the reporter gene which is restored in the 
presence of tetracycline/doxycycline due to release of tetR-KRAB from the DNA (Figure 7C). In 
addition, a Tet-OFF version of tetR-KRAB has also been generated (rtTS-KRAB) in which reporter 
gene expression is silenced in the presence of tetracycline/doxycycline (Figure 7D) (Szulc et al, 
2006). Current Tet-inducible systems with dual regulators: tTA and rtTS (Figure 7E) or rtTA, tTS 
(Figure 7F) have been generated to improve inducibility for this gene expression regulatory system. 
Yao et al described another version of the Tet system (T-REx) (Yao et al, 1998) which differs 
from the conventional Gossen and Bujard Tet-system (Gossen & Bujard, 1992) in number and 
placement of tetO sites. The T-REx system contains two tetO repeats located 10 bp 3’ to the CMV 
minimal promoter TATA box. Unlike the conventional Tet system, T-REx uses the whole tetR protein 
as repressor. 
1.2.2. Tetracycline-inducible gene expression in HSV-1 
Previous studies have reported successful use of the Tet-inducible system to regulate 
transgene expression in HSV-1 derived amplicon vectors. HSV-1 amplicons are plasmids bearing the 
expression cassette of gene of interest, the HSV-1 origin of replication and the HSV-1 packaging 
signal (Spaete & Frenkel, 1982). HSV-1 amplicons are packaged as concatemers of up to one viral 
genome length into HSV virions in the presence of a helper virus. Helper viruses are replication-
defective HSV-1 viruses containing mutations or deletions within an essential IE gene, such as ICP4 
(Geller et al, 1990). 
Ho et al incorporated the firefly Photinus pyralis luciferase reporter gene linked to the 
tetracycline-responsive promoter system into HSV-1 amplicon vectors and observed gene expression 
modulation both in vitro and in vivo (Ho et al, 1996). They observed 50-fold repression of gene 
expression in the presence of tetracycline which could be relieved, allowing maximal expression to be 
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reached within 10-12 hours after the removal of the antibiotic. In another Tet-OFF study, localized 
and high levels of β-galactosidase expression were observed in mice infected with an HSV-1 
amplicon vector encoding the Lac Z gene and transactivator tTA. Transgene expression was observed 
to be reduced tenfold in the presence of doxycycline (Fotaki et al, 1997). In a later study, Schmeisser 
et al tested different promoters linked to the tetracycline-responsive element (TRE) in an HSV-1-
based vector system to identify one with the maximum level of transgene induction. After testing 
constructs containing the TRE linked to: a minimal CMV promoter, or a minimal HSV-1 ICP0 
promoter or a truncated HSV-1 ICP0 promoter with only one TAATGARAT motif, they reported the 
highest level of transgene expression using the truncated ICP0 promoter but the highest relative 
induction (with respect to the presence and absence of antibiotic) using the CMV minimum promoter 
(Schmeisser et al, 2002). Inducible transgene expression from this vector system was observed for 
several days in irreversibly differentiated NT2 cells (NT2 neurons) (Schmeisser et al, 2002). 
Evidence for long-term transgene expression in HSV-1 vectors is provided by the study of 
Gao et al (Gao et al, 2006). They compared two vector designs: one where tTA and the Lac Z gene 
were expressed separately by tetO linked promoters and another where the Lac Z gene was expressed 
by a tetO linked promoter but a modified neurofilament heavy gene promoter was used to express 
transactivator tTA. The results showed that both vector designs supported inducible gene expression 
in vitro and in vivo for short term (4 days) but long-term (2 months) in vivo inducible expression was 
observed only from the vector expressing tTA from the modified heavy gene neurofilament promoter 
(Gao et al, 2006). 
Yao et al demonstrated Tet-regulated expression of the Lac Z gene in replication-defective 
HSV-1 vectors using the T-REx system (Yao et al, 1998). They replaced both copies of the ICP0 
coding sequence with gene sequences expressing tetR and the essential viral gene UL9 with tetO-
regulated Lac Z reporter gene and reported 300 to1000-fold tetracycline-regulated gene expression in 
different cell types (Vero, PC12 and NGF-differentiated PC12) (Yao et al, 2006). Similar efficient and 
regulated gene expression was observed in vivo following intracerebral and footpad inoculations in 
mice (Yao et al, 2006). Jiang et al in 2012 used this Tet-regulated HSV-1 vector to demonstrate a safe 
and efficacious method of vector delivery to rat brains (Jiang et al, 2012). They administered the Tet-
inducible HSV-1 vector intranasally in rats and detected Tet-inducible β-galactosidase expression in 
cortical neurons, olfactory bulb, hippocampus, striatum, cortex, medulla, cerebellum, ventricles, and 
nasal septum (Jiang et al, 2012). Curiously, they observed that the intranasal viral administration 
method was less cytotoxic than intravenous or stereotactic delivery methods (Jiang et al, 2012). 
1.2.3. Inducible control of HSV-1 Replication 
Until now, very few attempts have been made to artificially regulate HSV-1 replication. 
Evidence for inducible HSV-1 replication comes from the study of Yao et al. They constructed the Tet 
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inducible HSV-1 recombinant KTR27 (Yao et al, 2010) by placing ICP27 transcription under tetO 
control and replacing ICP0 coding sequences with gene sequences expressing tetR. They reported 
1000 to 250,000-fold inducibility with respect to viral titer of KTR27 mutant in response to 
tetracycline. Intratumoral inoculation of this mutant markedly inhibited tumor growth in a xenograft 
model of human lung cancer in nude mice and this effect could be efficiently controlled by local co-
delivery of tetracycline (Yao et al, 2010). 
Using a different approach, Preston et al constructed the conditional mutant in1820K carrying 
mutations in the genes encoding ICP0, ICP4 and VP16. The mutant in1820K contains a host range 
mutation of the ICP0 promoter, a temperature-sensitive mutation in ICP4 and an insertion in the VP16 
coding region which abolishes its IE gene transactivation function. Cultured cells could be infected by 
the in1820K mutant virus at an MOI of 5 without detectable cytopathology at the non-permissive 
temperature whereas the virus could undergo lytic replication to high titers in permissive conditions 
(Preston et al, 1997). These results indicate that VP16 manipulation could be an alternative approach 
to control viral replication by controlling the expression of all IE genes. However, since VP16 is a 
virion-associated structural protein, deletion of its gene may result in other effects on virus viability. 
As mentioned earlier, HSV-1 circularizes its linear genome in host cells after infection either 
by direct ligation of the terminal ends (Davison & Wilkie, 1981; Mocarski & Roizman, 1982; Strang 
& Stow, 2005) or through homologous recombination between directly repeated sequences of the 
linear genome (Yao et al, 1997). This process employs the cellular protein regulator of chromatin 
condensation-1 (RCC1) (Umene & Nishimoto, 1996). Both circularization and viral DNA synthesis of 
WT HSV-1 in the tsBN2 cell line (a baby hamster kidney cell line (BHK) that carries a temperature-
sensitive mutation in the gene encoding RCC1) were observed to be reduced but not abolished at the 
non-permissive temperature. When RCC1 was absent, negligible infectious WT progeny were 
detected (Strang & Stow, 2007), suggesting control of viral gene circularization as an alternative 
means to regulate viral replication. 
HSV-1 replication is complex due to involvement of a large number of viral as well as 
cellular factors. Since HSV-1 has complicated gene expression cascades, a convincing reasonable 
approach would be to regulate the virus at a very early step of infection. ICP0 is the first translated 
product of HSV-1 and based upon the functions which this protein carries out (as discussed earlier in 
this section), regulation of ICP0 expression may be a viable strategy to impose control over HSV-1 
replication. In the following section I have briefly discussed the basal and inducible activities of the 
ICP0 promoter, an understanding of which will be helpful in designing gene expression control 
systems. 
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1.3. ICP0 promoter elements 
The regulatory elements present in the ICP0 core promoter regions are illustrated in Figure 8. 
These elements are: TATA box (T), Sp1 binding site (S), ICP4 binding site (4), G-box (G), CCAAT 
box (C), F2 (F) factor binding site, NF-κB-like binding site (NF), TAATGARAT (TG) and 
TAATGARAT-like (TL) motifs (Davido & Leib, 1998; Douville et al, 1995). Most of these regions 
act as protein factor binding sites and contribute towards the transcriptional regulation of the ICP0 
gene. Cellular factors like Sp1, CCAAT enhancer binding protein and F2 bind to the ICP0 promoter 
and activate ICP0 expression. The ICP4 binding site in the ICP0 promoter serves as a repressive motif 
at which ICP4 binds and represses ICP0 transcription (Faber & Wilcox, 1986). The promoter region 
from -95 to -37 bp is important for constitutive ICP0 promoter activity in both neuronal and non-
neuronal cells. The inducible activity of the promoter lies in the region from -550 to -129 bp. ICP0 
promoter activity is regulated by both viral and non-viral factors. 
 
Figure 8. Schematic representation of the ICP0 promoter elements. 
Map of the regulatory elements of the ICP0 promoter located upstream of the transcriptional start site (rightward 
pointed arrow). These elements are: TATA box (T), Sp1 binding site (S), ICP4 binding site (4), G-box (G), 
CCAAT box-binding factor site (C), F2 binding site for an unidentified factor (F), consensus TAATGARAT 
motif (TG), TAATGARAT like sites (TL) and NF-κB-like binding site (NF). The location of these elements is 
shown (not to scale) relative to the transcriptional start site (+1). 
 
The ICP0 promoter has multiple TAATGARAT related motifs located at positions -576 to -
154 bp from the transcriptional start site (TSS), but one of these containing the complete octamer 
sequence ATGCTAATGATAT (located at -154 bp from TSS) was identified as the most responsive 
motif (Kwun & Jang, 2000). VP16 along with the cellular factors Oct-1 and HCF forms the VP16 
inducible complex (VIC) which binds to the complete TAATGARAT motif and after specific 
interactions with transcription factors strongly transactivates ICP0 transcription (Kristie & Roizman, 
1987; McKnight et al, 1987). The integrity of the ATGC portion is crucial for Oct-1/VP16 complex 
formation and mutation in this sequence results in loss of complex formation (Douville et al, 1995). 
Due to the presence of the overlapping octamer sequence (ATGCTAAT) other cellular octamer-
binding proteins compete with Oct-1 for binding to the TAATGARAT motif and repress VP16- 
mediated ICP0 transactivation (Douville et al, 1995; Kemp et al, 1990). Deletion of the 
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TAATGARAT motif removes the inhibitory effects of other Oct proteins (Oct-2.4 and Oct-2.5) on the 
ICP0 promoter (Thomas et al, 1998) suggesting the TAATGARAT motif as a mediator of both 
positive and negative effects of cellular transcription factors. Studies on VP16 show that its 
transactivation via VIC is short range and functions only from a promoter proximal position but can 
produce long range transactivation when fused to DNA-binding domains of other proteins (e.g. 
GAL4) (Hagmann et al, 1997). The inability of VP16 to transactivate from long distances could be a 
natural mechanism of the virus to ensure undesired long range effects on other viral promoters. 
In nature HSV-1 can transit between replicative (lytic) and silent (latent) life modes. The 
study in this thesis was carried out to test if this transition can be simulated in vitro by artificially 
imposing control over HSV-1 replication. Since HSV-1 replication is complex and involves a large 
number of cellular and viral factors, the most likeable approach to regulation would be to target the 
earliest step of the replication. ICP0 is the first translated product of HSV-1 and performs central 
functions in viral replication, latency maintenance and reactivation to the lytic cycle (see section 
1.1.5.2); therefore is an attractive candidate for manipulation to achieve the goal. In the present study 
I targeted ICP0 transcription and generated mutations in the ICP0 promoter, to examine the possibility 
of producing an “OFF” state with no viral growth, which can be switched to an “ON” state with 
efficient lytic replication. Within the ICP0 promoter I targeted the consensus TAATGARAT motif 
positioned at -154 bp relative to the TSS to control VP16 mediated activation of the ICP0 promoter. 
The idea was to test if the artificial tetracycline inducible system can functionally substitute for 
natural VP16-mediated transactivation. Specifically, it was investigated if specific binding of Tet 
system regulators (rtTA, tetR-KRAB) to the tetO sites can inducibly regulate ICP0 transcription and if 
this regulation can simulate control in viral replication. I observed that although deletion of the IR 
region from the HSV-1 genome does not significantly reduce viral growth in culture, this minimized 
genome became sensitive to additional mutations which have no phenotype in the wild-type genome: 
deletion of the ICP34.5 gene and alteration of the ICP0 promoter TAATGARAT element. 
Furthermore, distal displacement of the TAATGARAT element unexpectedly augments ICP0 
accumulation which considerably affects mutant replication. The present study indicates a strong 
dependence of productive infection on the complex kinetics of ICP0 processing, translocation and 
accumulation which cannot be mimicked by the binding of rtTA at tetO sites. 
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2. OBJECTIVES 
Amongst the five immediate-early (IE) genes of HSV-1, ICP4 and ICP27 are known to be 
essential for viral growth in culture, with regulatory functions in the viral lytic cycle (DeLuca et al, 
1985; Dixon & Schaffer, 1980; Preston, 1979; Sacks et al, 1985; Watson & Clements, 1978) whereas 
ICP22 and ICP47 are non-essential in vitro (Longnecker & Roizman, 1986; Post & Roizman, 1981). 
The requirement for ICP0 in viral replication however has been observed to be MOI dependent: ICP0 
is dispensable at high MOI but is essential at low multiplicity for viral gene expression and efficient 
progression of lytic infection. Analysis of an ICP0 null mutant (Stow & Stow, 1986) at the single cell 
level revealed a cell type-dependent MOI threshold above which the mutant virus replicates normally 
but below which it becomes quiescent (Everett et al, 2004; Sacks & Schaffer, 1987). Nonproductively 
infected cells can express viral proteins and mutant virus can enter either quiescence, produce stalled 
infections, or in some cases even initiate plaque formation (Everett et al, 2004; Sacks & Schaffer, 
1987). 
Considering the vital role of ICP0 in determining the fate of viral replication, the overall aim 
of this thesis was to test the hypothesis that productive HSV-1 lytic replication can be regulated by 
controlling ICP0 transcription. My approach consisted of the following specific aims: 
2.1. To verify if a single copy of repeat sequences is sufficient for HSV-1 
replication in vitro 
The HSV-1 genome has two copies of the IE genes - ICP0 and ICP4 which are present as 
direct and internal repeats. For my work on developing HSV-1 derived vectors, deletion of one set of 
these genes facilitates the unambiguous engineering of the other set. This can be achieved by 
homologous recombination in bacteria ((Muyrers et al, 1999; Zhang et al, 1998) reviewed in (Muyrers 
et al, 2001)). To test if a single copy of repeat sequences is sufficient for HSV-1 replication, I 
compared the in vitro titer of an HSV-1 mutant deleted for internal repeat sequences to that of the WT 
virus. 
2.2. To determine if ICP0 expression can be regulated artificially 
The tetracycline-inducible system (Gossen & Bujard, 1992) was utilized to regulate the 
transcription of the remaining copy of ICP0 in the HSV-1 mutant deleted for internal repeat 
sequences. This insertion of tetracycline-responsive elements were combined with the deletion of 
ICP0 promoter regulatory elements to generate potentially conditional mutants. The control of ICP0 
expression was assayed in cell lines expressing tetracycline transregulators in the presence or absence 
of doxycycline. 
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2.3. To determine the effect of ICP0 promoter mutations on ICP0 expression and 
HSV-1 replication 
The effect of ICP0 promoter manipulations on HSV-1 replication was analyzed by measuring 
the titer and ICP0 expression level of the mutants in infected Vero cells and cell lines expressing Tet 
regulators (transcriptional transactivators and silencers). 
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3. MATERIALS 
3.1. Reagents 
Dulbecco's Modified Eagle Medium (DMEM), Opti-MEM and TrypLE were purchased from 
Gibco/Life Technologies, Paisley, UK. Antibiotics used in cell cultures and bacterial cultures 
(penicillin, streptomycin, ampicillin, kanamycin, tetracycline, chloramphenicol), L-arabinose and 
doxycycline hyclate (Dox) were purchased from Sigma-Aldrich (St. Louis, MO). Puromycin was 
obtained from Gibco/Life Technologies (Grand Island, NY). Fetal bovine serum (FBS, product 
number F7524) was from Sigma-Aldrich (St. Louis, MO) whereas TRIzol, Lipofectamine-LTX and 
Plus reagents were purchased from Life Technologies (Carlsbad, CA). 
3.2. Bacterial strains 
Strain Genotype Source/ Ref 
DH10B F
–
 mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80dlacZΔM15 ΔlacX74 endA1 recA1 deoR 
Δ(ara,leu)7697 araD139 galU galK nupG 
rpsL λ- 
(Durfee et al, 2008; Grant 
et al, 1990) 
DH5α F
–
 Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK
–
, mK
+
) phoA 
supE44 λ–thi-1 gyrA96 relA1 
(Taylor et al, 1993) 
PIR1 F
–
 ∆lac169 rpoS(Am) robA1 creC510 
hsdR514 endA recA1 uidA(∆MluI)::pir-116 
Life Technologies 
(Carlsbad, CA), 
catalogue number- 
C1010-10 
 
3.3. Cell lines 
Cell line Origin Culture Media 
Source/Ref of the plasmid 
used for construction of 
stable cell lines 
Vero 
African green 
monkey kidney 
epithelial cell 
F10 medium: DMEM 
supplemented with 
10% FBS, 100U/ml 
ATCC* CRL 1586 (Earley 
EM, 1988 ) 
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penicillin and 100 
μg/ml of streptomycin 
Vero-
tetRKRAB 
Vero cell line 
expressing 
tetracycline 
repressor-KRAB 
fusion protein 
F10 medium 
supplemented with 
puromycin (3 μg/ml) 
pEFKRAB (see section 
4.2.4.2)  
Vero-rtTA 
Vero cell line 
expressing 
tetracycline reverse 
transactivator (rtTA) 
F10 medium 
supplemented with 
puromycin (3 μg/ml) 
(Mak et al, 2010) 
U2OS 
Human osteosarcoma 
cell line 
F10 medium (Yao & Schaffer, 1995) 
 
*ATCC is the registered trademark of the American Type Culture Collection. 
 
3.4. Virus 
The parental virus strain used in this study was strain F of HSV-1(Ejercito et al, 1968). The 
viral genome of strain F cloned in a bacterial artificial chromosome (BAC) plasmid (Tanaka et al, 
2003) was used for the construction of all the mutants. 
3.5. Plasmids 
Plasmid Selection marker Source / Ref 
pAXKS Ampicillin 
AseI/ XhoI fragment from cos6 ligated into 
pBluescriptKSII(+) 
pBluescriptKSII(+) Ampicillin (Alting-Mees & Short, 1989) 
Cos6 Ampicillin (Cunningham & Davison, 1993) 
Cos48 Ampicillin (Cunningham & Davison, 1993) 
pCTP Ampicillin (Saeki et al, 2001) 
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pDRIVE-CAG Zeocin Invivogen, San Diego, CA 
pEEHG Ampicillin (Wade-Martins et al, 2001) 
pEF-IRESP Ampicillin (Hobbs et al, 1998) 
pGEMT Easy Ampicillin Promega, A1360 
pGZSpe 
Ampicillin, 
Zeocin 
PCR amplified Sh ble gene using 
oligonucleotides PACSPE and UL5Z cloned 
into pGEMT Easy vector 
pI0prtTRK Ampicillin 
SpeI/NcoI pLVPRT-tTRKRAB and 
NcoI/EcoRI pAXKS ligated into SpeI/EcoRI 
pSKC481.9 
pI0prtTRZ 
Ampicillin, 
Zeocin 
NotI/SpeI pGZSpe cloned into NotI/SpeI 
pI0prtTRK 
pLD-puro-2A-rtTA-
TcVA 
Ampicillin, 
Puromycin 
Addgene, Cambridge MA, (Mak et al, 2010) 
pLOsG Ampicillin 
SalI/SpeI pEEHG blunted with Klenow and 
religated in presence of dNTPs 
pLOsG_Z Zeocin 
NotI/SpeI pGZSpe cloned into NotI/SpeI 
pLOsG 
pLVPRT-tTRKRAB Ampicillin 
Addgene, Cambridge MA, (Szulc et al, 
2006) 
pRSVβgal Ampicillin (Bonnerot et al, 1987) 
pSKC481.9 Ampicillin 
XhoI/EcoRI Cos48 ligated into 
pBluescriptSK 
pSK+Kana-RPSL Ampicillin, 
Addgene, Cambridge MA, (Wang et al, 
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Kanamycin 2009) 
pTetICP0B Ampicillin 
SacII/ BamHI fragment from Cos6 
(Cunningham & Davison, 1993) ligated into 
pUHD10-3  
pTGT0 
Ampicillin, 
Kanamycin 
XbaI/XhoI RP-Kan
R
 cassette (amplified 
using oligonucleotides TAAT and 
KANA3P) ligated into XbaI/XhoI 
pTetICP0B 
pUG6SP-tTA Ampicillin 
Addgene, Cambridge MA, (Zilio et al, 
2012) 
pUHC13-3 Ampicillin (Gossen & Bujard, 1992) 
pUHD10-3 Ampicillin 
Kind gift from Gossen, M, University of 
Heidelberg, Germany 
p175 Ampicillin (Perry et al, 1986) 
p∆34.5TGT0 
Ampicillin, 
Kanamycin 
XbaI/XhoI RP-Kan
R
 cassette (amplified 
using oligonucleotides ATN5 and 
KANA3P) ligated into XbaI/XhoI 
pTetICP0B 
p∆34.5T0 
Ampicillin, 
Kanamycin 
ligation of SacI/BamHI pAXKS (1.4 kb), 
XbaI/SacI p∆34.5TGT0 (1.76 kb) and 
XbaI/BamHI/SacI p∆34.5TGT0 (2.6 kb) 
fragments 
 
3.6. Oligonucleotides 
The following oligonucleotides were synthesized by Isogen Life Science. 
Name Sense Sequence (5’- 3’) 
AMP5’OUT Backward CCCACTCGTGCACCCAACTG 
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AMP3’OUT Forward CCCGTATCGTAGTTATCTAC 
ATN5 Forward 
   XbaI 
TCTAGACCGAGACTAGCGAGTTAGACAGGC
AAGCACTACTCGCCTCTGCACGCACATGTTA
ATTAAGTTTTATGGACAGCAAGCGAACCGG  
PacI 
CMVTATAFW Forward ATAGAAGACACCGGGACCGA 
C6B Backward AAGAACCCCATTAGCATG 
C3DRK  
CCCCGGGGACGGGGCCGCCCCTTAATTAAG
TTTTATGGACAGCAAGCGAACTAAGGTCGG
ACTCCGGATGGTGCCTCGAGTTTACCACTCC
CTATCAGTG 
C3DRK1 Forward AATGAGTTTCTTCGGGAAGG 
C3DRK2 Backward AAAACAGCGTGGATGGCCGTC 
ICP0TAfw Forward ATCACCACAGAAGCCCCGCCT 
ICP0E2rv Backward TTCGGTCTCCGCCTCAGAGT 
I34.53OUT Forward AGGCGGTCATCGGGCCGTG 
I4sen Forward CGACACGGATCCACGACCC 
I4ant Backward GATCCCCCTCCCGCGCTTCG 
KANA 3P Backward 
XhoI                          Filler sequence* 
CTCGAGGCACCATCCGGAGTCCGACCTTAG
CAATACCTTAATTAATCAGAAGAACTCGTC
AAGAAGGCGAT  PacI 
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KRAB200 Forward GCAAAAGTGAGTATGGTGCC 
KRAB3P Forward TCCCATCGAATTCGAAGTTGAG 
MARIZEO Forward CACTTTGTGGCAGAGGAGCAGGA 
PACSPE Backward GACTAGTTAATTAAGTTGAAAAAAGGGGCC 
RPREV Backward GGAGTGGTAGTATATACACGAG 
SEQK5 Forward CGTGCTTTACGGTATCGCCG 
SU1LOXHSV Forward TGCAGGAATTCGATATCAAG 
SU2LOXHSVUL4 Backward CGCCCTGGAATACGCAGACA 
TAAT Forward 
    XbaI 
TCTAGAGCATGCTAATGATATTCTTTGGGGG
CGCCGGGTTGGTCCCCGGGGACGGGGCCGC
CCCTTAATTAAGTTTTATGGACAGCAAGCGA
ACCGG     PacI 
Tet∆TGK3P Backward 
CCACCGCGGGGCGGCCCCGTCCCCGGGGAC
CAACCCGGCGCCCCCAAAGAGATCTCTATC
ACTGATAGGGAGATCTCTATCACTGATAGG
GAGTCAGAAGAACTCGTCAAGAA 
TN5PROM Backward TTCCCAACCTTACCAGAGGGCG 
∆TGR5P Forward 
TTCTTTGGGGGACACCGGGTTGGTCCCCCAA
ATCGGGGGCCGGGCCGTGCTATGGACAGCA
AGCGAACCGG 
US3A Backward 
AAATGTCGGCCATCCAGAAAACGTCCCGGA
GGACCACAGTGGCTTCCCCCCCAGTTACCA
ATGCTTAATCAG 
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UL5A Forward 
TTATAACCCCGGGGGTCATTCCCAACGATCA
CATGCAATCTAACTGGCTCGCACTTTTCGGG
GAAATGTG 
UL5Z Forward 
CTCGAGTTATAACCCCGGGGGTCATTCCCAA
CGATCACATGCAATCTAACTGGCTCAATTAA
ATTTTTCAAAAGTAGTTGAC 
 
*Filler sequence = 31 base-pair random DNA sequence inserted as a homologous arm for posterior 
deletion of the RP-Kan
R 
cassette in the Tet-inR mutant. 
3.7. Antibodies 
Primary  Secondary Dilution/ Assay 
Anti-ICP0 mouse 
monoclonal (Santa Cruz 
Biotechnology, Inc, CA) 
anti-mouse IgG peroxidase conjugate 
(1:2000) (Sigma-Aldrich, St. Louis, 
MO), Alexa-Fluor 488 conjugated anti-
mouse (1:500) (Molecular Probes/Life 
Technologies, Eugene, OR) 
1:500, 1:50 
Western, 
immunofluorescence 
(IF) 
Anti-ICP4 mouse 
monoclonal (Abcam, 
Cambridge, UK) 
anti-mouse IgG peroxidase conjugate 
(1:2000) (Sigma-Aldrich, St. Louis, 
MO) 
1:2000 
Western 
Anti-GAPDH mouse 
monoclonal (Abcam, 
Cambridge, UK) 
anti-mouse IgG peroxidase conjugate 
(1:2000) (Sigma-Aldrich, St. Louis, 
MO) 
1:3000 
Western 
Anti-HSV-1 rabbit 
polyclonal (Dako 
Cytomation, Glostrup, 
Denmark) 
anti-rabbit IgG peroxidase conjugate 
(1:2000) (Sigma-Aldrich, St. Louis, 
MO) 
1:1000 
Immunosubstrate 
staining 
Anti-PML rabbit 
polyclonal (Santa Cruz 
Biotechnology, Inc, CA) 
Alexa-Fluor 555 conjugated anti-rabbit 
(1:500) (Molecular Probes/Life 
Technologies,Eugene, OR) 
1:50 
IF 
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3.8. Buffers 
The following standard buffers were used in the experiments throughout: 
1X Tris-acetate (TAE) 40mM Tris, 20mM acetic acid, and 1mM EDTA 
1X Phosphate buffered saline 
(PBS) 
137mM NaCl, 2.7mM KCl, 10mM Na2HPO4 and 1.8mM 
KH2PO4 
1X Electrophoresis buffer 25 mM Tris, 192 mM glycine, 0.1% SDS 
1X Transfer buffer 48 mM Tris, 39 mM glycine, 10-20 % methanol 
1X TBST( Tris-Buffered Saline 
with Tween 20 ) 
50 mM Tris.HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20 
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4. METHODS 
4.1. MOLECULAR BIOLOGY TECHNIQUES 
4.1.1. Agarose gel electrophoresis 
1% (w/v) agarose gels were prepared using 1X TAE buffer (see section 3.8). SYBR Safe 
(Life Technologies, Paisley, UK) DNA gel stain was added to the mixture at a final concentration of 
1X. Loading buffer (10X: 1X TAE, 50% (v/v) glycerol, 0.025% bromophenol blue) was added to 
DNA samples prior to loading at a 0.1 volume. For DNA size markers a 10 kb DNA ladder (Thermo 
Scientific, Carlsbad, CA) was used in all gels. The bands were visualized on a Gel Logic 1500 
Imaging System (Eastman Kodak, Rochester, NY). 
4.1.2. Restriction enzyme digestions 
Restriction enzyme digests were performed on plasmid DNA in a total volume of 30 μl 
containing 0.5 μg (plasmid) - 2 μg (BAC) DNA, 0.5 - 1 μl restriction enzyme (10 U/μl), 3 μl of the 
appropriate restriction buffer (10X) as specified by the manufacturer (Thermo Scientific, Carlsbad, 
CA) and double-distilled water. The digests were incubated at 37°C from 1 hour to overnight 
followed by electrophoresis on a 1% agarose gel. The bands were visualized on a Gel Logic 1500 
Imaging System (Eastman Kodak, Rochester, NY). 
4.1.3. Elution and purification of DNA from gel bands 
A small hole was made in the bottom of a 0.5 ml microcentrifuge tube and was covered with 
glass wool. An agarose slice containing the DNA band of interest was excised using a clean scalpel 
and placed in the microcentrifuge tube on top of the glass wool. The tube containing the gel slice was 
then placed inside a larger (1.5 ml) microcentrifuge tube and centrifuged at 11,000 xg for 1 minute. 
The liquid obtained in the 1.5 ml microcentrifuge tube was collected and added to phenol at a ratio of 
1:1. The liquids were mixed by vortexing and then centrifuged at 11,000 xg for 5 minutes to separate 
the aqueous and organic phases. The upper aqueous phase was carefully collected with a pipette, 
transferred to a fresh 1.5 ml microcentrifuge tube and DNA precipitated by the addition of 0.1 
volumes 3M sodium acetate (pH 5.4), 3 volumes ethanol and 10 ng/μl of glycogen carrier. The tube 
was incubated at -20°C for 1 hour and then centrifuged at 11,000 xg for 30 minutes at 4°C. The DNA 
pellet obtained after centrifugation was washed once with 1 ml of 70% ethanol, air dried and 
dissolved in double-distilled water. The concentration of purified DNA was measured using a 
nanodrop spectrophotometer (ND-1000). 
4.1.4. DNA ligation reactions 
For each ligation reaction, 50 ng of vector DNA was mixed at a 1:3 molar ratio with the insert 
DNA along with 0.2 μl (5 U/μl) of T4 DNA ligase (Thermo Scientific, Carlsbad, CA) in ligase buffer 
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(Thermo Scientific, Carlsbad, CA) in a final volume of 10 μl. A control sample with no insert DNA 
was always included to reveal uncut or relegated vector. Reaction mixtures were incubated overnight 
at 16°C or 1 hr at room temperature. 
4.1.5. Polymerase chain reaction (PCR) 
For a 50 μl reaction, 1 μl of template DNA (1-50 ng) was added to a 0.2 ml PCR tube 
containing 10 μl GoTaq flexi buffer (5X), 4.8 μl 25 mM magnesium chloride (MgCl2), 1 μl 10 mM 
dNTPs (dATP, dTTP, dCTP and dGTP) mixture, 1 μl of each 5 mM oligonucleotide and 0.2 μl 
GoTaq DNA polymerase (5 U/μl, Promega). The volume was made up to 50 μl using double-distilled 
water. The PCR mixture was incubated in an automated thermocycler running the following 
amplification program: one cycle of 95°C for 5 min, 30 cycles of (1) 94°C for 30 sec, (2) 55-65°C 
(depending on the Tm of the oligonucleotides used) for 30 sec, (3) 72°C for 1 minute (depending on 
the length of the PCR product; ≈1 minute/ kb), and 1 cycle of 72°C for 5 minutes. PCR products were 
resolved on a 1% agarose gel and bands were visualized on a Gel Logic 1500 Imaging System 
(Eastman Kodak, Rochester, NY). 
4.1.6. RNA isolation and RT (reverse transcription)-PCR 
Cells were harvested for total RNA using TRIzol reagent, according to the manufacturer’s 
protocol. Briefly, cell monolayers were lysed in TRIzol reagent (1 mL TRIzol Reagent for a 35 mm 
culture dish) containing guanidinium thiocyanate. The cells were lysed directly in the culture dish by 
pipetting the mixture up and down several times and then collected into a 1.5 ml microcentrifuge tube. 
To extract RNA from the TRIzol preparation, 200 μl chloroform was added and the mixture was 
shaken vigorously by hand for 15 seconds. The mixture was incubated at room temperature for 3 
minutes and then centrifuged at 12,000 xg for 15 minutes to separate the 3 layers; lower red phenol-
chloroform phase, an interphase, and a colorless upper aqueous phase. The aqueous phase was 
collected carefully in a new 1.5 ml microcentrifuge tube and an equal volume of isopropanol was 
added. The mixture was incubated at room temperature for 3 minutes and then centrifuged at 12,000 
xg for 10 minutes to yield an RNA pellet. The pellet was washed with 75% ethanol and then dried at 
room temperature to ensure that no contaminating ethanol remained. Ribonuclease-free water was 
added (10-20 μl, depending on the size of the RNA pellet) and the RNA concentration was measured 
using a nanodrop spectrophotometer (ND-1000). 
2 μg RNA of each sample was reverse transcribed using random 6-mer primer (Invitrogen, 
Carlsbad, CA) and M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA). Samples were then 
analyzed in triplicate by PCR using oligonucleotides specific for ICP0 transcripts originating either 
from the native ICP0 start site (ICP0 TATA FW) or the CMV immediate-early minimal promoter start 
site (CMV TATA FW) and ICP0 exon II in reverse orientation (ICP0E2rv). The ICP4 transcripts were 
analyzed by PCR using oligonucleotide pair I4sen and I4ant. The sequences of oligonucleotides used 
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are listed in section 3.6. The PCR parameters used were: 21 cycles of 95°C for 30 sec, 58°C for 30 
sec, and 72°C for 1 minute. 
4.1.7. Luciferase assay 
After each treatment cells were washed with PBS and dry plates were frozen at -80°C until 
further use. To determine luciferase activity, cells were lysed and treated following the guidelines of 
the kit (Luciferase assay system, E1501, Promega), and analyzed in an AutoLumat LB953 
luminometer (Berthold Technologies). All experiments were performed in triplicate. Normalized 
luciferase activity represented in the graphs was the result of average relative light units (RLU) values 
obtained for each sample divided by the protein concentration. 
4.1.8. Western blotting 
4.1.8.1. Preparation of SDS-PAGE gels 
Gels for sodium dodecyl sulphate- polyacrylamide gel electrophoresis (SDS-PAGE) were cast 
by hand using components of the Mini-PROTEAN apparatus (Bio-Rad Laboratories, Inc.). Each gel 
consists of a lower resolving portion and an upper stacking portion. The resolving gel was prepared by 
mixing the following ingredients as shown in Table 1. 
Table 1. Composition of resolving gel 
Ingredients 
Volume (8% Acrylamide 
concentration) 
Water 5.3 ml 
30% Acrylamide/ Bis Acrylamide 2 ml 
1.5 M Tris-Cl (pH 8.0) 2.5 ml 
10% SDS 100 μl 
Ammonium persulphate 100 μl 
TEMED 6 μl 
 
The ingredients were mixed in a conical centrifuge tube (15 ml) and poured smoothly in between two 
glass plates, one short plate and one taller plate with gel spacer of 1.5 mm, aligned and secured within 
a casting frame supported on a gasket of a casting stand. The solution was overlaid with double-
distilled water and left to polymerize for 30 minutes. 
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Meanwhile, the mixture for stacking gel was prepared as follows: 
Table 2. Composition of stacking gel 
Ingredients Volume 
Water 4.1 ml 
30% Acrylamide/Bis Acrylamide 1 ml 
1 M Tris-Cl (pH 6.8) 750 μl 
10% SDS 60 μl 
Ammonium persulphate 60 μl 
TEMED 6 μl 
 
Once the resolving gel solidified, water was removed and the stacking gel mixture was poured 
over the resolving gel between the two glass plates. A 10 well or 15 well comb of 1.5 mm thickness 
was inserted in the stacking portion and left to polymerize for 30 minutes. 
4.1.8.2. Protein sample preparation 
Cells were collected, washed and resuspended in lysis buffer (50 mM Tris-HCl pH-8.0, 5 mM 
EDTA, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM sodium 
orthovanadate, 10 mM sodium fluoride and 1X proteinase-inhibitor mixture (Roche)). The cell debris 
was removed by centrifugation (10,000 xg for 10 minutes) and supernatant was collected. Protein 
concentration of the extracts was measured using the Dc protein assay kit (Bio-Rad, Hercules, CA). 
SDS sample buffer (5X) was prepared by mixing 0.25% bromophenol blue, 0.5 M 
dithiothreitol (DTT), 50% glycerol, 10% SDS and 0.25 M Tris-Cl (pH 6.8). 20% β- mercaptoethanol 
was added to the sample buffer before use. 25 μg of each cell lysates (see above paragraph) were 
mixed with sample buffer (0.2 volume) and heated at 100°C for 5 minutes before loading into the gel. 
4.1.8.3. Gel electrophoresis 
Once the stacking gel solidified, the comb was removed gently and the glass plates released 
from the casting frame and placed within the electrophoresis module assembly. The assembly was 
taken in a tank that was then filled with the electrophoresis buffer (section 3.8). Protein samples, 
prepared in SDS sample buffer (see above paragraph), along with a molecular weight standard (GE 
Healthcare) were loaded in the wells. The tank was covered with a lid bearing electrical cables to 
connect with a power supply with the proper polarity. Electrophoresis was carried out initially at 30 
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mA until the samples entered the resolving portion and then at 60 mA until the dye front reached the 
bottom of the gel. Once the gel run was over, the plates were removed and separated gently to take out 
the gel before setting transfer. 
4.1.8.4. Transfer of proteins to membrane 
The proteins resolved by gel electrophoresis were transferred to a piece of nitrocellulose 
membrane of 0.45 μm pore size (Whatman Protran) as follows: 
(1) Membranes were cut into 8.5 x 5.5 cm size and equilibrated in transfer buffer for 5-10 minutes. 
Two pairs of Whatman filter paper, cut to similar size, and one pair of fiber pads were similarly 
equilibrated. 
(2) The transfer was set up using the Mini Trans Blot apparatus (Bio-Rad Laboratories, Inc.). A gel 
sandwich was prepared within a gel holder cassette by placing sequentially one fiber pad, one pair of 
filter paper, the gel, the membrane, one pair of filter paper and the other fiber pad. Care was taken to 
eliminate any air bubble between the layers of the sandwich. 
(3) The cassette was carefully closed and placed in the electrode module with the gel facing the 
cathode end. The module was taken in a tank that was then filled with transfer buffer (section 3.8). 
The tank was covered with a lid bearing cables to connect with a power supply. Transfer was carried 
out at 200 mA for 2 hours at 4°C, following which the blotting sandwich was disassembled and the 
membrane was removed. To visualize the transferred proteins, the membrane was soaked in Ponceau 
S dye (0.1% (w/v) Ponceau S in 5% acetic acid), after which it was washed and processed for 
immunodetection. 
4.1.8.5. Immunodetection of proteins 
(1) The membrane was blocked for 1 hour at room temperature with blocking buffer (5% skimmed 
milk in TBST). 
(2) The membrane was incubated with primary antibody diluted in blocking buffer overnight at 4°C. 
(3) The membrane was washed 3 times for 10 minutes each with TBST. 
(4) The membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody 
(Sigma) diluted (1:2000) in blocking buffer for 1 hour at room temperature. 
(5) The membrane was washed 3 times for 10 minutes each with TBST. 
(6) Finally, the membrane was treated with Enhanced Chemiluminescence (ECL) detection reagents 
(PerkinElmer, Boston, MA) according to manufacturer’s protocol and exposed in a GE logic 1500 
imaging system (Eastman Kodak, Rochester, NY) to visualize antibody specific bands. Protein band 
densities were quantified using ImageJ software (Schneider et al, 2012). 
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4.1.9. Immunofluorescence (IF) assays 
Vero cells were grown on 12 mm glass coverslips and infected with viruses at an MOI of 1. 
Cells were fixed at 4, 8 and 24 hours post infection by incubating in a mixture of 95% ethanol and 5% 
glacial acetic acid for 5 minutes at -20°C (Everett & Murray, 2005). After fixation cells were blocked 
in blocking buffer (PBS containing 1% FBS and 0.2% Triton X-100) for 30 minutes at room 
temperature. The cells were incubated with rabbit polyclonal anti-PML (1:50) and mouse monoclonal 
anti-ICP0 (1:50) antibodies for overnight at 4°C. After incubation cells were washed 3 times with 
PBS containing 1% FBS followed by incubation with secondary antibody for 1 hour at room 
temperature. The secondary antibodies used were Alexa-Fluor 488 conjugated anti-mouse and Alexa-
Fluor 555 conjugated anti-rabbit (1:500, Molecular Probes/Life Technologies, Eugene, OR). Cell 
nuclei were counterstained with 4', 6-diamidino-2-phenylindole (DAPI) (1 ng/μl, Calbiochem, 
Nottingham, UK) for 10 minutes at room temperature, and mounted with Fluoromount-G (Southern 
Biotech Birmingham, AL). The samples were examined and images were taken using an Olympus 
IX81 microscope. ICP0 expression in virus-infected cells was quantified using ImageJ software 
(Schneider et al, 2012) 
4.1.10. Detection of ICP0 expression in single cell 
Vero cells were grown on 12 mm glass coverslips and infected with viruses at an MOI of 
0.007. Cells were fixed at 24 hours post infection and stained with anti-ICP0 antibody as described in 
the section 4.1.9. The secondary antibody used was Alexa-Fluor 488 conjugated anti-mouse (1:500). 
Mock-infected cells were used as negative control for ICP0 staining. Cell nuclei were counterstained 
with DAPI for 10 minutes at room temperature and mounted with Fluoromount-G. Cells on coverslips 
were photographed using an Olympus IX81 microscope. Images for all the samples were captured 
during the same session at exposure times of 47 and 1 ms for green and blue fluorescence 
respectively. The pixel density of ICP0 expression in single cells infected by viral samples was 
quantified using ImageJ software (Schneider et al, 2012). The background for staining was 
normalized by subtracting the mean pixel density of the mock-infected cell from the mean pixel 
density value of each sample. 
4.1.11. Detection of β-galactosidase expression 
The culture medium was removed from the infected plate and cells were washed twice with 2 
ml PBS and fixed with 1ml 4% paraformaldehyde (PFA) for 10 minutes at room temperature. The 
cells were washed three times with PBS and incubated at 37°C with 2 ml of pre-warmed X-gal 
solution (PBS supplemented with 2 mM MgCl2, 5 mM potassium ferrocyanide [K4Fe(CN)6].3H2O, 5 
mM potassium ferricyanide K3Fe(CN)6 and 1 mg/ml X-gal [5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside dissolved in Dimethylformamide]) until stained. The X-gal stain was then removed 
and the cells were washed with PBS. 
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4.1.12. Bacterial cell culture 
All bacterial cultures were grown in LB (lysogeny broth; (Bertani, 1951)) or semi-solid agar 
plates containing LB and bacterial agar (1.5% w/v). LB was autoclaved at 121°C for 20 minutes at 
15lb/inch
2
. Antibiotics were added as required just before use. 
4.1.13. Chemically competent cells preparation 
Competent cells used for transformation of plasmid DNA were prepared using the standard 
CaCl2 technique. A single bacterial colony was grown overnight in 3 ml of LB containing no 
antibiotics at 37°C. The saturated overnight culture was diluted 500-fold in 100 ml of LB containing 
no antibiotics. The cells were allowed to grow at 37°C until the optical density (OD) derived from 
absorbance measured at 600 nm reached between 0.3-0.4. Cells were pelleted by centrifugation at 
10,000 xg for 10 minutes at 4°C. The supernatant was discarded and the pellet resuspended gently in 
25 ml of ice-cold 100 mM MgCl2. Cells were pelleted as before, resuspended in 4 ml of ice-cold 100 
mM calcium chloride (CaCl2) and kept on ice for 10 minutes. Glycerol was added to the bacterial 
suspension to reach the final concentration of 10% (v/v). Competent cells were aliquoted and stored at 
-80°C until further use. 
4.1.14. Bacterial transformation 
Bacterial chemically competent cells were thawed on ice and 50 μl of cells were pipetted into 
1.5 ml microcentrifuge tubes for each transformation. 1-5 μl of ligation mix or 50 ng of plasmid DNA 
weas added to the cells, mixed gently and incubated on ice for 30 minutes. The cells were given heat 
shock for 30 sec in a 42°C water bath and tubes were placed on ice for 10 minutes. 950 μl of pre-
warmed SOC (super optimal broth (Hanahan, 1983) with 20 mM added glucose) was added to each 
tube and incubated at 37°C for 1 hour with agitation (1100 rpm). The transformed cells were plated in 
two different volumes on LB agar plates containing the appropriate antibiotic and incubated overnight 
at 37°C in a standard bacterial incubator. Two different volumes were taken to ensure that at least one 
plate will have well-spaced colonies. 
4.1.15. Colony screening by PCR 
Multiple bacterial colonies for each insert were picked up and amplified by PCR using one 
oligonucleotide annealing to the vector and another to the insert. PCR products were resolved on an 
agarose gel and positive clones were detected by the presence of band at the predicted size. 
4.1.16. Plasmid amplification 
Bacterial cultures were grown for the positive clones and plasmid DNA was extracted using a 
Qiagen Plasmid Mini/ Maxi preparation kit following the guidelines provided. 
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4.1.17. DNA sequencing 
Plasmid (100 ng/μl) and BAC (200 ng/μl) DNA were sequenced by the Secugen S.L 
sequencing service (Madrid, Spain). Oligonucleotides were synthesized by Isogen Life Science 
(Veldzigt, the Netherlands) and were used at a concentration of 5 µM. 
4.2. CELL CULTURE TECHNIQUES 
All cell culture solutions, media and supplements were obtained from Gibco. All 
manipulations of cells were carried out under sterile conditions using standard aseptic techniques. 
4.2.1. Freezing and recovery of cells 
Cells from one 100 mm cell culture dish were trypsinized, resuspended in 1.8 ml of freezing 
mixture (10% (v/v) dimethyl sulfoxide (DMSO) and 90% (v/v) FBS) and aliquoted in 2 cryovials, 
which were slowly cooled to -80°C by keeping in a cryobox containing 2- propanol and then stored in 
liquid nitrogen tank. 
DMSO is toxic above 4°C and thus when recovered, cells were rapidly thawed and 
centrifuged to minimize the toxic effects of the cryoprotectant. Cell pellets were gently resuspended in 
1 ml pre-warmed F10 medium and slowly transferred to 100 mm cell culture dishes with F10 
medium. 
4.2.2. Cell passage 
Cells were grown in 100 mm cell culture dish in appropriate media (section 3.3). They were 
incubated at 37°C/5% CO2 humidified cell incubator and routinely passaged when 75-80% confluent. 
The growth medium was carefully removed and the cell monolayer was gently washed with sterile 
PBS and incubated with 2 ml Tryp-LE (for 100 mm cell culture plate) until the cells were detached 
from the surface of the plate. 2 ml of F10 medium were added to the plate to neutralize the effect of 
Tryp-LE. The trypsinized cells were centrifuged in a 15 ml conical centrifuge tube at 200 xg for 5 
minutes. The obtained cell pellet was resuspended in a small volume of fresh medium and seeded at a 
ratio of 1:10 in appropriate cell culture medium (section 3.3). 
4.2.3. Cell line transfection 
Cells were transfected using the Lipofectamine-LTX and Plus reagent. A day prior to 
transfection, 1.6 X 10
5
 cells were seeded in a 35 mm cell culture dish to achieve 70% cell confluency 
on the day of transfection. In a sterile 1.5 ml microcentrifuge tube, 1 μg (plasmid) - 2 μg (BAC) DNA 
was diluted into 100 μl of Opti MEM medium and mixed with Plus reagent in a ratio of 1:2 (plasmid 
DNA) or 1:3 (BAC DNA). The mixture was incubated for 5 minutes at room temperature. In another 
microcentrifuge tube, 12 μl of Lipofectamine-LTX reagent was diluted in 100 μl of Opti-MEM and 
added to the DNA-Plus mixture. The Lipofectamine, DNA and Plus mixture was allowed to form 
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complexes over 20 minutes at room temperature. The cell culture medium was replaced with 0.8 ml 
Opti-MEM and the Lipofectamine-DNA-Plus mixture (200 μl) was gently added to the cells in drops. 
After 4 hours, the medium with transfection mixture was replaced with pre-warmed cell culture 
medium and cells were grown under normal conditions. 
4.2.4. Construction of stable cell lines 
4.2.4.1. Vero cell line expressing the reverse tetracycline-responsive transactivator (rtTA) 
Cell lines expressing rtTA (Vero-rtTA) were generated by transfection of Vero cells with the 
plasmid pLD-puro-2A-rtTA-TcVA (Mak et al, 2010) using Lipofectamine-LTX and Plus reagent as 
described in the section 4.2.3. Stably transfected clones were selected and maintained in F10 medium 
supplemented with puromycin (3 μg/ml). After recloning twice, the cell line with the highest 
inducibility of the rtTA transgene was identified by luciferase assay (E1501, Promega, Madison, WI) 
after transfection with a tetO-containing reporter plasmid (Gossen & Bujard, 1992). 
4.2.4.2. Vero cell line expressing the tetracycline repressor- Krüppel associated box (KRAB) 
(tetR-KRAB) fusion protein: 
Two oligonucleotides with complementary base pairing were synthesized; XLNK 
(TCGAGATCTACTAGT) and NLNK (CATGACTAGTAGATC). Both oligonucleotides were 
annealed together by mixing in equal volumes (at equimolar concentration) in a 1.5 ml 
microcentrifuge tube. The tube was heated in a standard heat block at 90-95°C for 3-5 minutes and 
then allowed to cool slowly at room temperature. This annealing generated a cohesive end compatible 
with those generated by XhoI restriction enzyme at one end of the annealed fragment (XLNK-NLNK). 
The EcoRI/NcoI tetR-KRAB fragment generated from double digestion of the plasmid pLVPRT-
tTRKRAB (Szulc et al, 2006) was ligated to the XhoI-XLNK-NLNK fragment. This ligation destroys 
the NcoI site from the tetR-KRAB fragment. The fragment obtained from the ligation (XhoI/EcoRI 
KRAB-XLNK-NLNK) was purified by ethanol precipitation method and cloned into the pEF-IRESP 
plasmid (Hobbs et al, 1998) digested with XhoI and EcoRI to generate the plasmid pEFKRAB. 
Cell lines expressing tetR-KRAB (Vero-tetRKRAB) were generated by transfection of Vero 
cells with the plasmid pEFKRAB using Lipofectamine-LTX and Plus reagent as described earlier (see 
section 4.2.3). Stably transfected clones were selected and maintained in F10 medium supplemented 
with puromycin (3 μg/ml). After recloning twice, the cell line with the highest tetR-KRAB-mediated 
transgene repression was identified by luciferase assay after transfection with a tetO-containing 
reporter plasmid (Gossen & Bujard, 1992). 
Both cell lines Vero-rtTA and Vero-tetRKRAB were used in the present study to analyze 
tetO-containing viral mutants. 
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4.3. HSV-1-BAC RECOMBINEERING 
4.3.1. Generation of HSV-1 mutants by homologous recombination 
The parental virus strain used in this study was strain F of HSV-1(Ejercito et al, 1968). The 
viral genome cloned in a bacterial artificial chromosome (BAC) plasmid (Tanaka et al, 2003) was 
used for the construction of all the mutants by lambda Red-mediated homologous recombination 
((Muyrers et al, 1999; Zhang et al, 1998) reviewed in (Muyrers et al, 2001)) following the guidelines 
provided with a commercial kit (Gene bridges, K001, version 2.7). Briefly, it involved the following 
steps: 
4.3.1.1. Generation of the linear targeting fragment flanked by homology arms 
for construction of HSV-1 mutants 
A targeting fragment containing an antibiotic selection marker gene flanked by homologous 
sequence arms stretches of DNA shared by the two molecules that recombine, was generated by PCR 
using customized oligonucleotides. The 5’ oligonucleotide consisted of a 50 nucleotide homology arm 
(which allows recombination with the homologous sequence 5’ of the intended insertion site), 
followed by a 20-nucleotide stretch which primes the 5’ end of the PCR amplification of the selection 
marker. The 3’ oligonucleotide was similarly constructed, with a stretch of 50 nucleotides that is 
homologous to the region 3’ of the intended insertion site, followed by a 20-nucleotide stretch that 
primes the 3’ end of the PCR amplification of the selection marker. 
For ∆IR construction, the targeting fragment was generated by PCR amplification of the beta 
lactamase (bla) gene (conferring ampicillin resistance) using oligonucleotides UL5A and US3A (see 
section 3.6) and plasmid pSK+KanaRpsL as template DNA. The recombination targeting fragments 
for mutants Tet∆34.5TG, Tet-in and Tet∆34.5 were respectively generated by digestion of plasmids 
p∆34.5TGT0, pTGT0 and p∆34.5T0 with EcoRI and PvuI restriction enzymes. Plasmid p∆34.5TGT0 
was constructed by ligating the XbaI/XhoI RP-Kan
R
 cassette into ptetICP0B. The RP-Kan
R
 cassette is 
composed of the E. coli ribosomal S12 (rpsL) gene (RP) which results in streptomycin sensitivity and 
the aminoglycoside phosphotransferase (aph) gene which confers kanamycin resistance (Kan
R
). The 
RP-Kan
R 
was generated by PCR using oligonucleotides ATN5 and KANA3P and pSK+KanaRpsL as 
template DNA (see section 3.6). Plasmid pTGT0 was derived in a similar manner as p∆34.5TGT0 but 
using oligonucleotides TGRAT and KANA3P. The sequences of the oligonucleotides used for PCR 
are listed in section 3.6. Plasmid p∆34.5T0 was generated by triple ligation of the 1.4 kb SacI/BamHI 
fragment from pAXKS, the 1.76 kb XbaI/SacI fragment from p∆34.5TGT0 and the 2.6 kb 
XbaI/BamHI fragment from p∆34.5TGT0. 
For mutant Tet∆34.5TG-K, linear fragment was generated by digestion of the plasmid 
pI0prtTRZ with PvuII restriction enzyme. 
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For mutant Tet∆TG construction, the targeting fragment was generated by PCR amplification 
of the RP-Kan
R 
cassette
 
using oligonucleotides ∆TGR5P and Tet∆TGK3P (see section 3.6) and 
pSK+KanaRpsL as template DNA. 
4.3.1.2. Transformation with Red/ET expression plasmid 
Glycerol stock of E. coli strain DH10B (Durfee et al, 2008; Grant et al, 1990) containing the 
target HSV-1 BAC was streaked on a LB agar plate conditioned with chloramphenicol (15 μg/ml). 
The plate was incubated overnight at 37°C in a bacterial incubator. 
Day 1: 1 colony from the streaked plate was picked and inoculated in a 1.5 ml microcentrifuge tube 
containing 1 ml of LB conditioned with chloramphenicol (15 μg/ml). A small hole in the lid was made 
for air passage. The tube was incubated at 37°C overnight with agitation (1100 rpm). 
Day 2: 2 microcentrifuge tubes were set up with 1.4 ml of LB conditioned with chloramphenicol (15 
μg /ml) and inoculated with 30 μl of the overnight culture. Tubes were then incubated at 37°C for 2 
hours with agitation (1100 rpm). 
After incubation, electrocompetent cells were prepared by centrifuging bacterial culture at 
11,000 xg for 1 minute at 2°C. The pellet was resuspended in ice-cold water and centrifuged again 
(11,000 xg, 2°C, 1 minute). This was repeated twice more and the cell pellet was resuspended in 50 μl 
ice-cold double-distilled water. Care was taken to maintain 4°C throughout the process. 
For transformation, 1 μl of the pRed/ET plasmid (100 ng) was added to the electrocompetent 
cells of one of the microcentrifuge tube and mixed gently. The other tube was used as electroporation 
control (without pRed/ET). Electroporation was performed in ice-cold cuvettes (Bio-Rad 
Laboratories, Inc., 1 mm electrode gap) using a Bio-Rad MicroPulser at 1.8 kV, untruncated time 
setting. After electroporation, 1 ml of pre-warmed SOC (super optimal broth (Hanahan, 1983) with 20 
mM added glucose) medium was added to the cuvettes to facilitate recovery of the cells which were 
then incubated at 30°C for 1 hour with shaking. Cells were spread onto LB agar plates containing 
chloramphenicol (15 μg/ml) and tetracycline (3 μg/ml) and incubated overnight in bacterial incubator 
at 30°C. 
4.3.1.3. Insertion in the HSV-1 genome of linear fragments with desired 
mutations using selection markers 
Day 1: A single colony was picked from LB plate containing Red/ET plasmid and target HSV-1 BAC 
and inoculated into a 1.5 ml microcentrifuge tube containing 1 ml LB broth with antibiotics 
(chloramphenicol 15 μg/ml, tetracycline 3 μg/ml). The tubes were incubated overnight at 30°C with 
agitation (1100 rpm). 
Day 2: Four 1.5 ml microcentrifuge tubes (2 for experiment and 2 for control) were set up with 1.4 ml 
fresh LB supplemented with 15 μg/ml chloramphenicol and 3 μg/ml tetracycline. The tubes were 
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inoculated with 30 μl of the saturated overnight culture of DH10B containing the target BAC and 
pRed/ET. All the four tubes were incubated at 30°C until the OD derived from absorbance measured 
at 600 nm reached between 0.3-0.4. Expression from the pRed/ET plasmid was induced in two tubes 
(1 from the experiment and 1 from the control) by addition of 50 μl of 10% L-arabinose and 
incubation for 45 minutes at 37°C before chilling on ice for 15 minutes. The electrocompetent cells 
were prepared as described above (see section 4.3.1.2). For transformation, 100 ng of the linear 
targeting fragment was added to the electrocompetent cells on ice (both L-arabinose-induced and 
uninduced experimental tubes). Electroporation was performed on all the four cultures (induced and 
uninduced experimental tubes, induced and un-induced control tubes) in ice-cold cuvettes (1 mm 
electrode gap) using a Bio-Rad MicroPulser at 1.8 kV, untruncated time setting. After electroporation, 
1 ml of pre-warmed SOC medium was added to the cuvettes to facilitate recovery of the cells which 
were then incubated at 37°C for 1 hour with shaking, inoculated onto LB agar plates containing 15 
μg/ml chloramphenicol and either 50 μg/ml ampicillin (for ∆IR) or 15 μg/ml kanamycin (for TetICP0 
mutants) or 25 μg/ml zeocin (for Tet∆34.5TG-K) and incubated overnight at 37°C (restrictive 
temperature for pRed/ET). The next day, several independent colonies were picked and tested for 
correct recombination by colony PCR or restriction digest analysis of purified BAC DNA. 
4.3.1.4. Generation of the HSV-1 mutant Tet-inR by RP-kanamycin counter 
selection 
The Tet-inR mutant was generated by negative selection to remove the RP-Kan
R
 dual marker 
which confers streptomycin sensitivity (Wang et al, 2009). The 100-base pair single-stranded 
oligonucleotide (C3DRK; see section 3.6) consisting of the 50 nucleotides flanking either side of the 
RP-Kan
R
 cassette was used as the targeting fragment to generate the deletion in the Tet-in mutant by 
lambda red-mediated homologous recombination as described above, and the Tet-inR mutant was 
selected by growth in medium containing 5 mg/ml streptomycin. 
4.3.2. Cre recombinase-mediated site-specific DNA insertion into HSV-1 BAC in 
E. coli 
Mutant Tet∆34.5TG-O was generated by Cre recombinase-mediated site-specific 
recombination (Kim et al, 1998). Electrocompetent bacterial cells containing HSV-1 BAC DNA 
(Tet∆34.5TG) were prepared as described above in the section 4.3.1.2. The cells were electroporated 
with a mixture containing 10 ng each of the temperature sensitive (ts) helper plasmid pCTP-T (which 
expresses Cre recombinase in trans) and the insertional shuttle plasmid pLOsG_Z (which contains a 
loxP site, oriS, the green fluorescent protein (GFP) reporter gene (gfp) and the Sh ble gene (conferring 
zeocin resistance)). After electroporation, cells were resuspended into 1 ml SOC medium containing 
heat-inactivated tetracycline (20 μg/ml) to induce Cre expression and incubated for 4 hours at 30°C 
(permissive temperature for the helper plasmid pCTP-T) with shaking. The integrated recombinants 
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(Tet∆34.5TG-O) were selected at 43°C (restrictive temperature for the pCTP-T) on LB agar plates 
supplemented with chloramphenicol (15 μg/ml), kanamycin (15 μg/ml) and zeocin (25 μg/ml). 
4.3.3. Verification of modified HSV-1 BAC by DNA sequencing 
DNA of HSV-1 mutants were sent to the sequencing service for the final confirmation using 
oligonucleotides reading across the recombination junction. The oligonucleotides used for sequencing 
of HSV-1 mutants are listed in Table 3. 
Table 3. Oligonucleotides used for sequencing of HSV-1 mutants. 
Mutant Oligonucleotides Used for Sequencing 
∆IR AMP5’OUT, AMP3’OUT 
Tet∆34.5TG RPREV, SEQK5 
Tet-in RPREV, TN5PROM, SEQK5 
Tet-inR C3DRK1, C3DRK2 
Tet∆34.5 RPREV, SEQK5, C6B 
Tet∆TG SEQK5, TN5PROM, I34.53OUT 
Tet∆34.5TG-K KRAB3P, KRAB200, MARIZEO 
Tet∆34.5TG-O SU1LOXHSV, SU2LOXHSVUL4 
 
4.4. VIRAL PROPAGATION TECHNIQUES 
4.4.1. Viral stock preparation 
4.4.1.1. Seed stock 
Approximately 1.6 X 10
5 
Vero cells were seeded in a 35 mm cell culture dish to obtain 70% 
cell confluency on the day of transfection. Cells were transfected with 2 μg of BAC DNA encoding 
viral genome using Lipofectamine-LTX and Plus reagent as described earlier in the Methods. After 4 
hours of transfection, cells were overlaid with 0.7% sterile agarose dissolved in F2 medium (DMEM 
supplemented with 2% FBS, 100U/ml penicillin and 100 μg/ml of streptomycin) and incubated at 
37°C until the viral plaques were visible. A single plaque was picked using a P 20 Gilson pipette, 
stabbing through the agarose into the cells. The agarose plug plus the cells was transferred into a 0.5 
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ml microcentrifuge tube containing 40 μl of FBS and stored in -80°C until further use. A single 
plaque was used to infect fresh Vero cells seeded in a 35 mm culture dish. Cells were harvested when 
cytopathic effects (CPE, generally 1-2 days) became visible in all cells, by three freeze-thaw cycles 
followed by sonication to release intracellular viral particles into the supernatant. Cell debris was 
removed by centrifugation (2,000 xg for 5 minutes) and clarified supernatant was collected and stored 
at -80°C in aliquots. 
4.4.1.2. Master stock 
The viral seed stock was then amplified to prepare master stock. Approximately 2 X 10
6 
Vero 
cells were seeded in a 100 mm cell culture dish and infected with 50 µl of seed stock in 6 ml of F2 
medium. After 1-2 days when cells became round but remained anchored to the culture dish, they 
were scraped into their own medium using a sterile plastic cell scraper. The viral preparation was 
stored in aliquots at -80°C after completing 3 cycles of freeze-thaw and sonication and centrifugation 
steps as described for seed stock preparation. 
4.4.2. Viral stock titration 
Virus titers were measured by infecting Vero cells with different dilutions of viral preparation 
in F2 medium. After absorption for 90 minutes, the medium was replaced with 0.7% sterile agarose 
dissolved in F2 medium. After overnight incubation, cells were fixed with 4% PFA and the agarose 
was removed. Cells were incubated in blocking buffer (PBS containing 1% FBS and 0.2% Triton X-
100) for 30 minutes at room temperature and subsequently incubated with a rabbit polyclonal anti-
HSV-1 antibody (1:1000) for 2 hours at room temperature. After incubation, cells were washed 3 
times in PBS and then incubated with anti-rabbit secondary antibody/peroxidase conjugate (1:2000, 
Sigma-Aldrich, St. Louis, MO) for 1 hour at room temperature. Peroxidase-labeled cells were 
visualized by incubating in a mixture of 0.05% 3, 3’-Diaminobenzidine (DAB; Acros Organics) and 
0.015% hydrogen peroxide (H2O2; Panreac, Barcelona, Spain) for 5 minutes. The DAB mixture was 
removed and cells were washed once with PBS to stop the staining process. Bright field photographic 
images were used to count the number of HSV-1 positive cells (stained brown) using the ImageJ cell 
counter plug-in (Schneider et al, 2012) to calculate infectious HSV-1 particle titer. 
4.4.3. In vitro viral growth curve 
For viral growth curve experiments, approximately1.8 X 10
5
 cells were seeded in 35 mm cell 
culture dishes and infected with viruses at stated MOIs. Cells were incubated at 37°C for 90 minutes 
to allow the virus to be absorbed after which inocula were replaced with F2 medium and the cultures 
incubated at 37°C for indicated times. Progeny viruses were harvested by lifting the cells with a 
plastic scraper into the medium which was then subjected to three freeze-thaw cycles followed by 
sonication. The cell lysate was centrifuged at 2,000 xg for 5 minutes and titration of the viral 
supernatant was performed on monolayer of Vero cells as described in the above paragraph. 
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For transfection experiments, 2 μg of BAC DNA encoding viral genome was transfected in a 35 mm 
cell culture dish of Vero cells using Lipofectamine-LTX and Plus reagent. Cells were harvested at 
specified times and viral titers were measured over fresh Vero cells. 
4.4.4. One step growth kinetics 
For single cycle growth assays Vero cells were infected at an MOI of 5 for 1 hour, after which 
the cells were washed twice with PBS and re-incubated in F2 medium until harvested for virus 
titration. Supernatants and cells were harvested separately to estimate titer of extracellular and 
intracellular viral particles. 
4.4.5. Focus formation assay 
Vero cells were infected at the indicated MOI for 90 minutes, after which the cells were 
overlaid with 0.7% sterile agarose dissolved in F2 medium for stated time points. Cells were then 
fixed with 4% PFA and stained with rabbit polyclonal anti-HSV-1 antibody as described in the virus 
titration section (4.4.2). Cells were imaged by bright field microscopy and focus area was measured 
using ImageJ software (Schneider et al, 2012). 
4.4.6. Drug treatments 
To inhibit protein synthesis, 200 μM cycloheximide (Sigma-Aldrich, St. Louis, MO) was 
added to Vero cells 0.5 hour prior to viral inoculation and was maintained in cultures until the viral 
inoculum was replaced with fresh F2 medium containing either 300 μM acyclovir (Calbiochem, 
Billerica, MA) or 10 μg/ml actinomycin D (Sigma-Aldrich, St. Louis, MO) or no drug (vehicle only). 
4.5. STATISTICAL ANALYSIS 
Statistical comparison of the data sets was performed by Student’s t test. The differences are 
given with their corresponding P value, which is the probability that the difference occurred merely 
by chance under the null hypothesis. 
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5. RESULTS 
5.1. Generation of the ∆IR mutant: deletion of the internal repeat (IR) sequences 
has little effect on HSV-1 growth in Vero cells 
The WT HSV-1 genome consists of two repeated regions- IR and TR. The ∆IR mutant was 
constructed by deleting the IR sequences from the WT genome using bacterial homologous 
recombination as described in the Methods. The IR deletion removes one copy of all the duplicated 
regions present in the viral genome which include the genes encoding ICP0, ICP4, ICP34.5, the 
packaging signal and oriS. This deletion ensures unambiguous targeting of any subsequent 
mutagenesis and increases viral genomic stability by eliminating rearrangements due to isomerization 
of the unique segments (UL/US). The structure of the ∆IR genome compared to the WT genome is 
illustrated in Figure 9A. The HSV-1 strain F (Ejercito et al, 1968) genome cloned in a bacterial 
artificial chromosome (BAC) (Tanaka et al, 2003) has four BamHI restriction enzyme sites in the IR 
region. Candidate ∆IR mutants generated by homologous recombination were checked for loss of 
these restriction sites by digesting purified BAC DNA with BamHI enzyme followed by 
electrophoresis in a 0.8% agarose gel (Figure 9B). The deletion boundaries were further confirmed by 
PCR and DNA sequencing. The ∆IR master stock was generated as described in Methods and could 
be grown up to titers similar to WT. 
The effect of IR deletion on HSV-1 replication was first tested by evaluating multi-cycle 
growth kinetics in Vero cells using an MOI of 0.1. The growth curve exhibited by the ∆IR mutant is 
indistinguishable from that of WT, indicating a negligible effect of the IR deletion on overall viral 
titer (Figure 9C). Measurement of viral progeny release in single step kinetics using an MOI of 5 also 
revealed little differences in the rate of increase in infectious particle concentrations either in the 
intracellular or extracellular fractions although at early time points the titer of extracellular ∆IR 
particles was 30%-70% of that of WT, suggesting a slight defect in virion egress which is no longer 
evident at 24 hours post infection (Figure 9D). 
Following this observation I examined the effects of IR deletion on viral replication initiated 
in the absence of virion components by transfection of viral genomic DNA. The WT or ∆IR BAC 
DNA was transfected into Vero cells and viral titer was measured in cell extracts harvested at 24, 32, 
48 and 56 hours post transfection. As a control for transfection efficiency of the BAC DNAs, the 
number of immunopositive cells for HSV-1 antigen was counted in parallel transfected samples fixed 
at 8 hours post transfection. This value was used to normalize respective WT and ∆IR titers measured 
at all the time points. The ∆IR mutant showed a reduced viral titer per transfected cell compared to 
WT in this assay (Figure 9E), indicating a slight defect in growth in the absence of virion 
components. 
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Figure 9. Characterization of the HSV-
1 mutant ∆IR deleted for the internal 
repeat region. 
A. Schematic representation of genomes 
of wild type HSV-1 (WT) and ∆IR. The 
unique long (UL) and the unique short 
(US) segments are shown flanked by the 
internal repeat (IR) and the terminal 
repeat (TR). The unique origin of 
replication oriL is present in the UL 
segment (L enclosed by circle). The 
immediate early genes encoding ICP0 and 
ICP4, the origin of replication oriS (S 
enclosed by circle) and the packaging 
signal (a and a’) are present in the WT 
genome in duplicate copies, one of which 
has been deleted in the ∆IR mutant. The 
∆IR mutant was constructed by replacing 
one copy of ICP0, ICP4, ICP34.5, one 
packaging signal and one origin of 
replication by the beta lactamase (bla) 
gene conferring ampicillin resistance 
(ampR). Vertical lines over IR represent 
four BamHI restriction enzyme sites 
which are eliminated by the ∆IR mutation. 
B. Agarose gel electrophoresis pattern of 
WT and ∆IR BAC DNA digested with 
BamHI enzyme. Leftward red arrows 
show band differences due to the loss of the BamHI sites in the IR region. 
C. Growth kinetics of WT (circles, solid line) and the ∆IR mutant (diamonds, dotted line) in Vero cells infected 
at a multiplicity of infection (MOI) of 0.1. 
D. Growth kinetics of WT and the ∆IR mutant in Vero cells infected at an MOI of 5 showing titers of 
intracellular (in) viral particles (WT;solid circles and ∆IR; solid diamonds) and extracellular (ex) viral particles 
(WT; open circles and ∆IR; open diamonds). 
E. Growth kinetics of WT (circles, solid line) and the ∆IR mutant (diamonds, dotted line) after transfection of 
BAC DNA in Vero cells. 
Graphs in C and E show mean values and error bars indicating the standard deviation of three independent 
experiments. 
 
These results indicate that though ∆IR initially exhibits slow replication in the absence of 
virion proteins, the final titer after multi-cycle replication in Vero cells is not adversely affected, 
indicating that only a single copy of all the genetic elements in HSV-1 is sufficient for viral 
replication in culture. 
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5.2. Generation of ∆IR mutants with ICP0 promoter modifications 
The ∆IR backbone was next used to generate mutants in the region upstream of the single 
ICP0 open reading frame to identify possible strategies to impose control over HSV-1 lytic 
replication. A first set of mutant genomes was constructed (Figure 10) in which tet operator (tetO) 
sites were inserted: (1) between the ICP0 transcription start site (TSS) and the TAATGARAT motif, 
displacing the latter 1.5 kb further upstream (Figure 10A, mutant Tet-in); (2) replacing all of the ICP0 
promoter up to TAATGARAT as well as the upstream ICP34.5 gene (Figure 10A, mutant 
Tet∆34.5TG). Deletion of both copies of the ICP34.5 gene in the WT genome has previously been 
observed to be non-deleterious for viral replication in cell lines (Chou et al, 1990; Kesari et al, 1998) 
and so to confirm that ICP34.5 is also non-essential for viral growth in culture in the context of the 
∆IR backbone, a third construct was generated in which tetO sites were inserted to replace only the 
ICP34.5 gene, leaving the ICP0 promoter region intact (Figure 10A, mutant Tet∆34.5). 
 
Figure 10. Mutation of the ICP0 
promoter region in ∆IR by tetO 
insertion. 
A. Diagram of the HSV-1 terminal repeat 
(TR) region showing the ICP34.5 gene, 
the consensus TAATGARAT motif (TG) 
and the TATA box (TATA) upstream of 
the transcription start site (rightward 
arrow) of the ICP0 gene, all of which are 
present as a single copy in the ∆IR 
mutant. Three ICP0 promoter mutants 
were constructed by insertion of the RP-
KanR/tetO cassette, composed of: the E. 
coli ribosomal S12 (rpsL) gene (RP) 
which results in streptomycin sensitivity; 
the aminoglycoside phosphotransferase 
(aph) gene which results in kanamycin 
resistance (KanR); target-binding sites for 
the E. coli tetracycline repressor 
consisting of 7 tet operator (tetO) 
sequences. In the Tet-in mutant, the RP-
KanR/tetO cassette was inserted in  
between the TG motif and the TATA box. In the Tet∆34.5TG mutant, the RP-KanR/tetO cassette replaced the 
whole region encompassing the ICP34.5 gene up to and including the TG motif. In the Tet∆34.5 mutant, only 
the ICP34.5 gene was replaced by the RP-KanR/tetO cassette. 
B. Agarose gel electrophoresis analysis of ∆IR-derived genomes containing mutations in the ICP0 promoter 
treated with restriction enzymes. BAC DNA encoding the Tet-in mutant was digested with AseI and that 
encoding the Tet∆34.5TG and Tet∆34.5 mutants was digested with NcoI restriction enzymes. The parental BAC 
encoding ∆IR was used as a control in all the digestions. Leftward red arrows show band differences due to the 
mutations in the ICP34.5 gene and ICP0 promoter region. 
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All three TetICP0 mutants listed above were generated by homologous recombination in 
bacteria using linear targeting fragments derived from plasmids pTGT0, p∆34.5TGT0 and p∆34.5T0 
respectively as described in the Methods. The structures of the mutant genomes compared with the 
∆IR genome were verified by digestion of their encoding BAC DNA with restriction enzymes 
followed by electrophoresis in a 0.8% agarose gel: for the Tet-in mutant, AseI was used, while for the 
mutants Tet∆34.5TG and Tet∆34.5, NcoI was used. Leftward red arrows in Figure 10B indicate 
changes in restriction digest patterns of BAC DNA of mutants Tet-in, Tet∆34.5TG and Tet∆34.5 
compared to that of ∆IR. The deletion junctions were further confirmed by PCR and DNA 
sequencing. 
5.3. Phenotypic characterization of TetICP0 mutants 
To test whether mutations in the ICP0 promoter and its upstream region produce phenotypic 
changes, the TetICP0 mutants were characterized by timing the appearance of the first plaques and 
quantifying the spread of infection in vitro. BAC DNA encoding either the WT, ∆IR, Tet-in, 
Tet∆34.5TG or Tet∆34.5 mutant genome was transfected into Vero cells in semi-solid medium, and 
stained with anti-HSV-1 antibody 1, 2, 4 and 6 days post-transfection. 
5.3.1. Plaque formation 
The WT virus grew rapidly in Vero cells with the appearance of the first plaque early on day 
3 after transfection. On day 4 all cells in the plate appeared infected with round morphology and many 
medium to big plaques were evident. Nearly all cells were lysed early on day 6 after transfection. 
Compared to WT, the ∆IR mutant showed reduced viral replication with the appearance of the 
first plaque late on day 3 after transfection. This observation correlates with the earlier result (section 
5.1) where ∆IR showed slow replication in absence of virion proteins. Transfection of DNA encoding 
the modified genomes revealed different viral growth for each of the three TetICP0 mutants. The Tet-
in mutant exhibited slower viral production in Vero cells with plaques appearing 4 days after 
transfection, compared to 3 days for the ∆IR mutant, consistent with a negative effect of the 
displacement of the TAATGARAT element on ICP0 expression. On day 6, numerous Tet-in plaques 
were filled in by overgrowth of surrounding non-productive cells. In Tet∆34.5TG-transfected cells, 
syncytia and very small plaques were often visible on day 4 but all such signs of viral growth 
disappeared by day 6. In cells transfected with mutant Tet∆34.5 the first plaque appeared late on day 
3, similar to ∆IR and the number of plaques increased from day 3 to day 6. 
5.3.2. Infection spread 
In the present study, infection spread was quantified by measuring the sum of the area of foci 
at various time points. Small infection foci of WT were observed on day 1 post-transfection which 
spread exponentially to cover the whole plate by day 2 (Figure 11A). On day 4 numerous large 
plaques were evident in the cell monolayer which was lysed completely on day 6 due to the viral 
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replication. In the ∆IR-transfected plate, small foci were observed on day 1 which increased on 
average, 225-fold in area by day 6 resulting in infection spread to the whole plate (Figure 11A and 
11B). Compared to WT, ∆IR replication appeared slower, since on day 6, cells were observed infected 
with visible plaques but remained attached to the plate (Figure 11A). The infection spread in TetICP0 
mutants- Tet-in and Tet∆34.5 appeared slower compared to the parental ∆IR mutant (Figure 11, 
approximately 21% and 30% of ∆IR infection spread on day 6) The Tet∆34.5TG mutant containing a 
deletion in ICP34.5 gene and a compromised ICP0 promoter was observed to have the slowest and 
most restricted infection spread amongst all the constructed TetICP0 mutants (approximately 5% of 
∆IR infection spread on day 6). 
Taken together, these results demonstrate that although ICP34.5 is nonessential for viral 
replication (Chou et al, 1990); its role becomes significant when ICP0 expression is compromised, 
such as in the case of the Tet∆34.5TG mutant. 
 
Figure 11. Spread of infection in Vero 
cells transfected with WT, ∆IR or 
TetICP0 mutants in semi-solid medium. 
A. Vero cells were transfected with DNA 
(as indicated to the left of each row) 
encoding the TetICP0 mutants (Tet-in, 
Tet∆34.5TG or Tet∆34.5), control viruses 
(WT or ∆IR) or the control plasmid 
pRSVβgal, which marks transfected cells 
by β-galactosidase expression. Cells were 
fixed on various days following 
transfection (indicated above each column) 
and stained with anti-HSV-1 antibody 
(WT, ∆IR and TetICP0 mutants) to detect 
virus-producing cells, or with 5-bromo-4-
chloro-3-indolyl-beta-D-galacto-
pyranoside (pRSVβgal), as a control for 
the apparent increase of transfected cells 
merely due to cellular duplication. Scale 
bar: 100 μm. 
B. Quantification of mean infection focus 
area at 1, 2, 4 and 6 days after transfection 
of WT (solid line, circles) and each 
mutant: ∆IR (dashed line, diamonds); Tet-
in (dashed/dotted line, squares), 
Tet∆34.5TG (dashed/double dotted line, 
solid squares) and Tet∆34.5 (dotted line, 
triangles). Error bars represent the standard 
error from analysis of 5-12 foci for each 
data point. 
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5.4. Simultaneous deletion of ICP34.5 and TAATGARAT motif abolishes viral 
replication 
Since transfection of Tet∆34.5TG BAC DNA yielded very small plaques which eventually 
became overgrown by nonproductive cells, I was unable to obtain viral stocks of mutant Tet∆34.5TG 
in multiple experiments. Cell lysates prepared at different time points revealed negligible infectious 
particles of Tet∆34.5TG (Figure 12A and 12C). Additionally, when checked for amplicon packaging 
ability, the Tet∆34.5TG mutant displayed highly reduced efficiency compared to WT, ∆IR and other 
TetICP0 mutants (Tet-in and Tet∆34.5) (Figure 12B). 
 
Figure 12. Effect of ICP0 promoter mutations on infectious particle production and amplicon packaging 
efficiency. 
A. Vero cells were transfected with DNA encoding the TetICP0 mutants (Tet-in, Tet∆34.5TG or Tet∆34.5) or 
control viruses (WT or ∆IR). At 48 hours post transfection, virus was prepared, plated over fresh Vero cells 
which after 24 hours were stained with anti-HSV-1 antibody to detect the presence of infectious particles. 
Representative images of these infectious particle assays for each viral mutant are shown. 
B. Vero cells were co-transfected with pHSVlac amplicon and DNA encoding the TetICP0 mutants (Tet-in, 
Tet∆34.5TG or Tet∆34.5) and control viruses (WT or ∆IR). At 48 hours post transfection, virus was prepared, 
plated over fresh Vero cells which after 24 hours were stained with 5-bromo-4-chloro-3-indolyl-beta-D-galacto-
pyranoside (X-gal) to detect the presence of packaged amplicons. Representative images of these amplicon 
packaging assays for each virus are shown. 
C. The plus (+) signs in the right column indicate growth of each mutant in Vero cells. Mutant Tet∆34.5TG 
exhibited slow formation of HSV-1 antigen positive foci after transfection of BAC DNA (represented as plus 
(+) sign enclosed in brackets) but all attempts to propagate it were unsuccessful. 
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These results suggest that the viral infection spread (see section 5.3.2) does not necessarily 
reflect successful establishment of productive infection. Moreover, negligible packaged virions were 
obtained for the Tet∆34.5TG mutant. The inability of the Tet∆34.5TG mutant to yield increasing titers 
of virion particles is not merely due to deletion of the ICP34.5 gene since transfection of the control 
construct Tet∆34.5 yielded viral growth similar to ∆IR. Productive infection could not be achieved 
even by transfection of the Tet∆34.5TG mutant into reverse tetracycline responsive transactivator 
(rtTA) expressing Vero (Vero-rtTA) cells, indicating that the deletion in Tet∆34.5TG results in a 
defect in ICP0 expression which cannot be compensated for by the tetracycline-regulated 
transactivation system. 
Next, complementation of the replication defect in Tet∆34.5TG mutant was attempted by (1) 
co-transfecting the mutant BAC DNA with a plasmid expressing ICP0 (pAXKS) in Vero cells or (2) 
performing the transfection in human osteosarcoma cell line U2OS. Both of these strategies failed to 
rescue Tet∆34.5TG mutant replication and negligible yields of infectious particles were obtained. 
Failure of Tet∆34.5TG to give measurable titers in the U2OS cell line which is known to support 
growth of ICP0 null mutants (Yao & Schaffer, 1995) suggests that in the absence of ICP34.5, ICP0 
executes an essential function which is not complemented by the U2OS cell line. 
To test if growth defects in Tet∆34.5TG are due to the deletion of the consensus 
TAATGARAT motif, another mutant Tet∆TG was generated which contains the ICP34.5 gene and all 
the ICP0 promoter elements but not the consensus TAATGARAT motif, which was substituted by 2 
tetO repeats (2X tetO, Figure 13A). The 2X tetO instead of 7 tetO repeats (as used in Tet∆34.5TG 
and the other TetICP0 mutants) was used since this has been shown to be equally functional in earlier 
studies (Marzio et al, 2001; Verhoef et al, 2001) and the smaller size facilitated construction. In Vero 
cells or the Vero-rtTA cell line, transfection of Tet∆TG BAC DNA results in productive infection and 
packages infectious particles (Figure 13C) with more growth in Vero-rtTA cells than in Vero cells 
(data not shown). The results indicate that mutant viruses constructed in the background of the ∆IR 
mutant are able to grow when either ICP34.5 (mutant Tet∆34.5) or the ICP0 TAATGARAT motif 
(mutant Tet∆TG) are mutated, but fail to replicate when mutations are made simultaneously in both. 
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Figure 13. Effect of the ICP34.5 gene, the ICP22 promoter and oriS on Tet∆34.5TG replication. 
A. Diagram of the HSV-1 terminal repeat (TR) region showing the ICP34.5 gene, the consensus TAATGARAT 
motif (TG) and the TATA box (TATA) upstream of the transcription start site (rightward arrow) of the ICP0 
gene, all of which are present as a single copy in the ∆IR mutant. In the Tet∆34.5TG mutant, the RP-KanR/tetO 
cassette replaced the whole region encompassing the ICP34.5 gene up to and including the TG motif. The RP-
KanR/tetO cassette consists of: the E. coli ribosomal S12 (rpsL) gene (RP) which results in streptomycin 
sensitivity; the aminoglycoside phosphotransferase (aph) gene which confers kanamycin resistance (KanR); 
target binding sites for the E. coli tetracycline repressor consisting of 7 tet operator (tetO) sequences. In the 
Tet∆TG mutant, the consensus TAATGARAT sequence was replaced by the RP-KanR cassette and 2 repeats of 
tetO sites (2X tetO). 
B. In the Tet∆34.5TG-K mutant, a linear fragment containing the tetracycline repressor-Krüppel-associated box 
domain fusion protein (tetR-KRAB) and the Sh ble gene conferring zeocin resistance (ZeoR) was inserted to 
replace the beta-lactamase (bla) gene conferring ampicillin resistance (ampR) of Tet∆34.TG. Transcription of 
the Sh ble gene was driven by the synthetic prokaryotic EM7 promoter (EM7-P) derived from the bacteriophage 
T7 promoter while the tetR-KRAB transgene was controlled by the ICP0 promoter (ICP0-P), an immediate 
early promoter of HSV-1. This mutation also inserts an origin of replication (oriS) and reconstitutes the ICP22 
promoter in the mutant genome. The open boxes on the right side represent the terminal repeat (TR) region of 
HSV-1 showing the packaging signal (a’), the RP-KanR/tetO cassette and the ICP0 gene. 
The plus (+) signs in the right column indicate varying degrees of growth of each mutant in Vero cells. 
C. Vero cells were transfected with DNA encoding WT, Tet∆34.5TG, Tet∆TG and Tet∆34.5TG-K. At 48 hours 
post transfection, virus was prepared and plated over fresh Vero cells which after 24 hours, were stained with 
anti-HSV-1 antibody to detect the presence of infectious particles. Representative images of the infectious 
particle assays obtained for each viral mutant are shown. 
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In addition to ICP34.5, ICP0, ICP4, packaging signal and oriS, the IR region of HSV-1 also 
contains part of the promoter of ICP22 gene which is deleted in the ∆IR mutant. Owing to this 
mutation the ∆IR and ICP0 mutants constructed on the ∆IR backbone may be defective in ICP22 
expression. Observations from another set of experiments showed that the defect in Tet∆34.5TG 
replication was overcome when the mutant genome was modified by reconstituting the ICP22 
promoter and inserting an extra copy of the origin of replication (oriS). The generated mutant 
Tet∆34.5TG-K (Figure 13B) produces infectious particles (Figure 13C) and could be grown up to 
titers similar to Tet∆34.5 (data not shown). This mutation was part of a separate set of experiments 
where I inserted the tetracycline repressor-Krüppel-associated box (KRAB) domain fusion proteins 
(tetR-KRAB) (Deuschle et al, 1995; Margolin et al, 1994) into the TetICP0 mutant genomes (Tet-in, 
Tet∆34.5TG and Tet∆34.5) to regulate ICP0 transcription via binding to the tetO sites. The objective 
of these experiments was to produce an “OFF” state with no viral growth, which can be switched to 
an “ON” state with efficient lytic replication. The regulatory effects due to the tetR-KRAB fusion 
protein were not observed in these TetICP0 mutants, but all exhibited enhanced viral replication such 
that even the modified Tet∆34.5TG mutant became replication-competent. 
To test if this rescue of Tet∆34.5TG replication was due to the insertion of oriS or 
reconstitution of the ICP22 promoter or both, another mutant was constructed, in which an extra oriS 
was inserted ectopically at the loxP site of the Tet∆34.5TG genome using Cre recombinase-mediated 
retrofitting (Figure 14A) (Kim et al, 1998). Transfection of Vero cells with the generated 
Tet∆34.5TG-O mutant (Figure 14A) containing two copies of oriS (one at TR and another at the loxP 
site) yielded micro-plaques on day 4 (Figure 14B). The plaques however became overgrown by non-
productive neighboring cells after a few days and negligible infectious particles were obtained. 
These results therefore indicate that simultaneous deletion of both the consensus 
TAATGARAT motif of the ICP0 promoter and the ICP34.5 gene disables viral growth (Tet∆34.5TG) 
in culture and the presence of either of them (as in Tet∆34.5 and Tet∆TG respectively) is necessary 
for maintenance of the viral replication. As the IR deletion also removes the ICP22 promoter, the 
growth defect in Tet∆34.5TG could also be partially contributed due to the absence of functional 
ICP22 at immediate early times of infection. Experiments with Tet∆34.5TG-K mutant confirmed that 
resurrection of the ICP22 promoter and insertion of oriS can rescue the growth defect in Tet∆34.5TG. 
This rescue is ICP22-dependent as the insertion of oriS alone fails (Tet∆34.5TG-O) to reproduce the 
effect. However, further experiments need to be done to test if reconstituting the ICP22 promoter 
alone is sufficient. 
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Figure 14. Cre recombinase-mediated 
insertion of the origin of replication 
(oriS) in the Tet∆34.5TG mutant. 
A. Schematic representation of Cre 
recombinase-mediated insertion of oriS at 
the loxP site of the Tet∆34.5TG mutant. 
The shuttle plasmid, pLOsG_Z, contains a 
loxP site, oriS, the green fluorescent protein 
(GFP) reporter gene (gfp), the Sh ble gene 
(which confers zeocin resistance; ZeoR) and 
the R6Kγ-ori (which enables replication 
only when π protein is supplied in trans). 
The temperature-sensitive (ts) helper 
plasmid pCTP-T contains a pSC101-derived 
thermosensitive replication origin; the TcR 
gene conferring tetracycline resistance 
sequences for tetracycline-inducible Cre 
expression, PIR; pir gene to supply the π 
protein to support the replication of the co-
introduced plasmids containing the R6Kγ-
ori. Electrocompetent E. coli (DH10B) 
bacteria containing Tet∆34.5TG BAC DNA 
were transformed with the pLOsG_Z shuttle 
plasmid and the pCTP-T helper plasmid. 
The integrated recombinants (Tet∆34.5TG-
O) were selected at 43°C on LB agar plates 
supplemented with chloramphenicol and 
zeocin. 
B. Vero cells expressing reverse tetracycline responsive transactivator protein (Vero-rtTA) were transfected 
with bacterial artificial chromosome (BAC) DNA encoding Tet∆34.5TG-O. Representative images of a micro-
plaque obtained on day 4 of transfection in bright field (left) and showing GFP autofluorescence (right). 
 
5.5. Mutant Tet∆34.5TG expresses immediate early and late proteins 
The ICP0 expression level in Tet∆34.5TG was subsequently analyzed to test if the replication 
failure of the mutant in vitro is due to insufficient availability of ICP0. The expression of a late HSV-
1 protein glycoprotein C (gC) was also checked in parallel to uncover if the mutant (Tet∆34.5TG) is 
able to complete the DNA replication process. BAC DNA encoding the WT or one of the mutant- ∆IR 
and Tet∆34.5TG genomes was transfected into Vero cells and immunostained with anti-ICP0 and 
anti-gC antibodies at 8, 24, 32, 48, and 56 hours post transfection. In parallel, the number of anti-
HSV-1 immunopositive cells was counted at 8 hours after transfection to normalize the transfection 
efficiency of the BAC DNAs. Figure 15A displays representative images of cells stained with each 
antibody. Quantification of the immunopositive cells revealed a continuous increase in the number of 
anti-ICP0 stained cells from 8 hours to 56 hours in WT-transfected culture. Cells transfected with ∆IR 
and Tet∆34.5TG displayed a similar trend but with values lower than the WT (approximately 4-fold< 
WT, Figure 15B). Anti-gC staining was evaluated in cells 24 hours after transfection with WT or 
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mutant DNA. Curiously, cells transfected with Tet∆34.5TG were observed immunopositive for gC 
antigen although with values lower than those of WT and ∆IR (approximately 6-fold< WT and 2-
fold< ∆IR) (Figure 15C). 
 
Figure 15. Kinetics of an immediate early (IE) and a late (L) protein in the Tet∆34.5TG mutant. 
A. Vero cells were transfected with DNA encoding the mutant Tet∆34.5TG and control viruses (WT and ∆IR). 
Cells were fixed at 8, 24, 48 and 56 hours post transfection after which they were stained with antibodies 
specific for the immediate-early (IE) protein ICP0 or the late (L) protein glycoprotein C (gC). As a control for 
transfection efficiency of the BAC DNAs, the number of immunopositive cells for HSV-1 antigen was counted 
in parallel transfected samples fixed at 8 hours. Representative images of Vero cells transfected with DNA as 
indicated to the left of each row and stained with antibody as indicated above each column are shown. Scale bar 
100 μm. 
B and C. Quantification of the number of immunopositive cells for ICP0 (B) or gC (C) protein in WT (solid 
line, circles), ∆IR (dashed line, diamonds) or Tet∆34.5TG (dashed/double dotted line, squares)-transfected 
samples. Error bars represent the standard error from three independent experiments. 
 
ICP0 is a polyprotein which translocates between the nucleus and the cytoplasm of infected 
cells at different times after infection (Lopez et al, 2001). Cells transfected with Tet∆34.5TG DNA 
exhibited similar numbers of ICP0 positive cells as those transfected with ∆IR DNA but failed to 
produce infectious particles, indicating a possibility of defective intracellular localization kinetics of 
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ICP0 in the mutant. The presence of gC staining, however, indicates that Tet∆34.5TG is able to carry 
out DNA replication and hindrances to growth occur after that event. 
5.6. Viral replication is impaired in ∆IR mutants with ICP0 promoter 
modifications 
Viral stocks of Tet-in and Tet∆34.5 were next prepared to perform a more detailed analysis of 
the growth of these mutant viruses in Vero cells (Figure 16A-D). Using an MOI of 1, growth of the 
Tet-in mutant was observed to be drastically reduced (Figure 16A, approximately 7% of ∆IR titer at 
24 hours) while Tet∆34.5 was less affected (Figure 16A, approximately 58% of ∆IR titer at 24 hours) 
but at a lower MOI, growth of Tet∆34.5 was also severely diminished (Figure 16B, approximately 
5% of ∆IR titer at 24 hours), while Tet-in replication was even more retarded (Figure 16B, 
approximately 0.5% of ∆IR titer at 24 hours). 
 
Figure 16. Characterization of the TetICP0 mutants. 
A and B. Growth kinetics of wild type HSV-1 (WT) (solid line, circles), the ∆IR mutant (dashed line, 
diamonds), the Tet∆34.5 mutant (dotted line, triangles) and the Tet-in mutant (dashed/dotted line, squares) in 
Vero cells infected at a multiplicity of infection (MOI) of 1 (A) and at an MOI of 0.1 (B). The combined 
intracellular and extracellular titer of infectious particles was measured at 3,6,9 and 24 hours post-infection. 
C. Viral spread in Vero cell monolayers overlaid with agar. Cells were infected with each mutant (∆IR, 
Tet∆34.5 or Tet-in as indicated to the left of each row) at several MOIs (0.001, 0.01 or 0.1 as indicated above 
each column), fixed after 48 hours and stained with anti-HSV-1 antibody. Representative infection foci for each 
sample are shown except for ∆IR at an MOI of 0.1 – all cells were lysed and detached from the plate during the 
staining process. Scale bar: 200 μm. 
D. Quantification of mean infection focus area at the 3 different MOIs for each mutant: ∆IR (dashed line, 
diamonds); Tet∆34.5 (dotted line, triangles); Tet-in (dashed/dotted line, squares). Error bars represent the 
standard error from analysis of 7-10 foci for each data point. 
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Next, viral spread was analysed by infecting Vero cells in semi-solid medium with each 
mutant at low MOI and examining infection foci after 48 hours (Figure 16C). Quantification of the 
average focus area (Figure 16D) revealed that at an MOI of 0.001, infection foci produced by 
Tet∆34.5 were only slightly smaller than those produced by ∆IR but this lower viral spread of 
Tet∆34.5 became more evident at higher MOIs. The Tet-in mutant showed even further impairment 
with much smaller infection foci at all MOIs tested (Figure 16D). These results support our 
hypothesis that ICP0 expression is perturbed in both mutants, since the replication of ICP0 mutants is 
known to be MOI dependent (Everett et al, 2004; Sacks & Schaffer, 1987). 
5.7. VP16 binding to the modified ICP0 promoter using the Tet-ON system or by 
restoring TAATGARAT proximity increases viral titer 
To test whether the reduced growth of Tet-in was a consequence of displacing the 
TAATGARAT motif by insertion of the RP-Kan
R
 cassette, the next mutant Tet-inR (Figure 17A) was 
generated using a negative selection strategy to delete the antibiotic marker cassette as described in 
the Methods. Transfection of Tet-inR DNA yielded virus which grew faster than the parental Tet-in 
mutant, with plaques appearing after 3 days. To investigate the role of VP16 transactivation of the 
ICP0 promoter on the replication of these mutants, the viral titers were analyzed at 24 hours after 
infecting Vero and Vero-rtTA cells at an MOI of 0.1. Figure 17B shows that in Vero-rtTA cells, titers 
of the Tet-in mutant were significantly higher (approximately 2-fold) than in Vero cells, indicating 
that the inserted tetO sites can compensate for the displaced TAATGARAT motif in this mutant, 
although not completely to WT levels. Removal of the 1.5 kb displacement in the Tet-inR mutant 
restored titers in Vero cells to the same level as in Vero-rtTA cells. Titers of the WT virus in Vero and 
Vero-rtTA cells were indistinguishable, confirming that the observed effect was mediated through the 
tetO sites. No significant difference in titer was observed by growth of Tet∆34.5 in Vero and Vero-
rtTA cells, indicating that the tetO sites in this mutant are probably too distant from the ICP0 TSS to 
regulate viral replication. 
Curiously, although the presence of rtTA significantly increased viral replication of the Tet-in 
mutant, the presence of doxycycline did not affect the growth of Tet-in or any of the other tetO-
containing mutants (Figure 17B). This result indicates that: (1) in the absence of doxycycline, rtTA 
can mimic VP16-mediated transactivation of ICP0 expression but (2) increased DNA-binding of rtTA 
in the presence of doxycycline does not offer further advantage for viral replication. 
Comparison of the different mutants to WT virus in this experiment revealed a small drop in 
titer of Tet∆34.5 (down to approximately 24% of WT titer) and a much larger decrease in Tet-in and 
Tet-inR (down to approximately 2-4% of WT titer). These data indicate that deletion of the ICP34.5 
gene results in a modest reduction of viral titers but that the ICP0 promoter modification and tetO 
insertion in the Tet-in and Tet-inR mutants significantly impairs viral replication. 
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Figure 17. Effect of the reverse 
tetracycline responsive transactivator 
(rtTA) on ICP0 promoter mutants with 
tetO insertions. 
A. Schematic representation of the ICP0 
promoter region showing the consensus 
TAATGARAT motif (TG), the TATA box 
(TATA) and transcription start site 
(rightward arrow) of the ICP0 gene in the 
wild-type HSV-1 (WT) genome. In the Tet-in 
mutant, the TG motif was displaced 1.5 
kilobase (kb) from its original position by 
insertion of the RP-KanR/tetO cassette, 
composed of: the E. coli ribosomal S12 
(rpsL) gene (RP) which results in 
streptomycin sensitivity; the aminoglycoside 
phosphotransferase (aph) gene which results 
in kanamycin resistance (KanR); target 
binding sites for the E. coli tetracycline 
repressor consisting of 7 tet operator (tetO) 
sequences linked to the minimal 
cytomegalovirus (CMV) immediate early 
promoter. In the Tet-inR mutant, the TG 
motif was returned closer to its original 
position by RP-KanR selection cassette 
deletion, leaving four intact tet operator 
(tetO) sequences. 
B. Viral titers of WT and the three mutants Tet∆34.5, Tet-in and Tet-inR at 24 hours after infection at a 
multiplicity of infection (MOI) of 0.1 in Vero cells, or Vero cells expressing rtTA in the absence of doxycycline 
(rtTA -Dox) or in the presence of doxycycline (rtTA +Dox). Histogram represents mean values of three 
independent experiments. Error bars indicate standard errors. Statistically significant increases (Student’s two-
tailed t-test) in titer with respect to the Tet-in titer in Vero cells are indicated by asterisks (** P < 0.002, Tet-in 
titer in rtTA-expressing Vero cells in the absence of doxycycline; * P < 0.02, Tet-in titer in rtTA-expressing 
Vero cells in the presence of doxycycline) and by the hash sign (# P < 0.05, Tet-inR titer in Vero cells). 
 
5.8. ICP0 protein levels are abnormally elevated as a result of TAATGARAT 
displacement in the ICP0 promoter 
Next, the effects of the tetO insertions on ICP0 protein expression were analyzed in western 
blots from cells lysates prepared 24 hours after infection at an MOI of 1 (Figure 18A). In all samples, 
in addition to the 110 kDa band corresponding to full-length ICP0, a 66 kDa band was also observed 
which has previously been described as due to the major proteolytic cleavage product of ICP0 (Gu et 
al, 2009). Since multiple factors affect the kinetics of this cleavage, the intensities of both bands were 
quantified (Figure 18B and 18C) to characterize the effects of the tetO insertions on ICP0 translation 
as well as processing. 
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Figure 18. ICP0 protein expression by mutants 
in the promoter region. 
A Western blot of lysates made from Vero cells or 
Vero cells expressing reverse tetracycline 
responsive transactivator (rtTA) after infection by 
wild-type HSV-1 (WT), Tet∆34.5, Tet-in and Tet-
inR mutants at a multiplicity of infection (MOI) of 
1 for 24 hours. Negative control lysates made 
from mock-infected cells (Mock) did not exhibit 
any ICP0-specific immunoreactivity whereas 
various ICP0 polypeptides could be detected in 
infected cells, including full-length (110 kDa) 
ICP0, and major cleavage products of 66 kDa and 
37 kDa. 
B and C. Histograms representing relative protein 
quantity of the 110 kDa species (B) and the 66 
kDa cleavage product (C) derived by densitometry 
of the electrophoretic bands shown in A, 
expressed as a percentage of the total protein 
quantified. Mean values from three independent 
experiments are shown, with error bars 
representing the standard error. Statistically 
significant differences (Student’s two-tailed t-test) 
with respect to the WT values in respective cell 
lines are indicated by asterisks (** P < 0.007; * P 
< 0.05). 
D. Viral titers of WT and mutant viruses 
(Tet∆34.5, Tet-in and Tet-inR) at 24 hours after 
infection at an MOI of 0.007 in Vero or U2OS cell 
line. Histogram represents quantification of the 
number of positive cells for anti-HSV-1 staining 
in both cell types infected by viral samples. Error 
bar represents the standard error from three 
independent experiments. 
 
 
 
In Vero cells, both ICP0 bands were detected at similar levels in extracts from the Tet∆34.5 
mutant compared to WT virus. An unexpected finding was an abnormally high level of the ICP0 
bands (approximately 15-fold > WT for 110 kDa band; 5-fold > WT for 66 kDa band) in the Tet-in 
mutant. Removal of the 1.5 kb displacement of the TAATGARAT element in the Tet-inR mutant 
resulted in reduction of full-length ICP0 expression down to intermediate levels (with respect to WT 
and Tet-in) for both the full-length 110 kDa protein (approximately 9-fold > WT) as well as the 66 
kDa cleavage product (approximately 4-fold > WT). 
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In Vero-rtTA cells, ICP0 expression following infection by WT virus or the Tet ∆34.5 mutant 
was similar to that observed in Vero cells. However, in the Tet-in and Tet-inR mutants, full-length 
ICP0 was expressed at slightly higher levels compared to that in Vero but this difference was not 
significant. Curiously ICP0 expression by the mutants in rtTA cells was unaffected by the presence of 
doxycycline except for Tet∆34.5, in which full-length ICP0 levels appeared to be higher, although this 
difference was not statistically significant (Figure 18B and 18C). 
Since the titer of all the viruses used in this study was measured in Vero cells, we next 
investigated if the observed ICP0 overexpression in Tet-in and Tet-inR could be attributed just to the 
underestimation of infectious particles since plaque formation by ICP0 mutants in Vero cells is known 
to be MOI dependent and a similar effect may apply to our infectious particle assay, which depends 
on HSV-1 antigen expression in infected cells. We carried out this assay for WT and ICP0 mutants 
(Tet-in, Tet-inR and Tet∆34.5) in the U2OS cell line which is known to complement ICP0 mutants 
(Yao & Schaffer, 1995) and the obtained titers were compared those measured simultaneously in Vero 
cells. The histogram in Figure 18D displays the titers measured in both the cell types when infected at 
low multiplicity (MOI 0.007). All the viruses showed similar infectious particle counts in both Vero 
and U2OS cell lines except the Tet-in mutant which displayed almost double the titer in U2OS 
compared to that of Vero cells. Normalization of the ICP0 quantification obtained in western blot 
using these titers measured in U2OS cells revealed that ICP0 levels were still elevated in the Tet-in 
mutant (approximately 7-fold > WT for the 110 kDa band) indicating that this effect was not merely 
due to infection of the mutant virus at a higher MOI compared to WT. 
To better understand the effect of the mutations on ICP0 expression kinetics, ICP0 level was 
measured in Vero cells infected for different times with WT, Tet-in and Tet-inR mutant at an MOI of 
1. The results revealed that the level of full length ICP0 (110 kDa) increased continuously from 8 
hours to 48 hours post-infection in all the viruses (Figure 19A and 19B). However, the peak level of 
the cleaved products (66 kDa and 37 kDa) in WT was observed at 32 hours after which the level 
decreased, possibly due to degradation of the cleaved products (Gu et al, 2009) (Figure 19A and 
19B). In contrast, the expression of the 66 kDa cleaved product in Tet-in and Tet-inR infected cells 
appeared to increase continuously from 8 hours to 48 hours whereas the peak expression of 37 kDa 
cleaved product was achieved earlier than WT (Figure 19A and 19B). 
Taken together, these results suggest that not only ICP0 protein levels are elevated 
abnormally in the Tet-in and Tet-inR mutants but that the kinetics for ICP0 cleavage and degradation 
are also altered. 
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Figure 19. Kinetics of ICP0 protein expression by WT virus and ICP0 promoter mutants. 
A. Western blot of lysates made from Vero cells after infection by wild-type HSV-1 (WT), Tet-in and Tet-inR 
mutants at a multiplicity of infection (MOI) of 1 for 8, 24, 32 and 48 hours (as indicated on the top of the blot). 
Various ICP0 polypeptides could be detected in infected cells, including full-length (110 kDa) ICP0, and major 
ICP0 cleavage products of 66 kDa and 37 kDa. 
B. Graphs representing protein expression level as a percentage of the maximum value of full-length ICP0 (110 
kDa) and the cleavage products (66 kDa, 37 kDa) derived by densitometry of the electrophoretic bands shown in 
A: WT (solid line, circles), Tet-in (dashed/dotted line, squares) and Tet-inR (dotted line, triangles). 
 
5.9. Single cell analysis confirms elevation of ICP0 protein level in the Tet-in 
mutant 
As an alternative approach to test whether ICP0 levels in Tet-in and Tet-inR infected cells are 
altered with respect to WT levels; we infected Vero cells with WT virus and the ∆IR, Tet∆34.5, Tet-in 
and Tet-inR mutants at high dilution (MOI of 0.007) and analyzed the samples after 24 hours by 
immunocytochemistry using an anti-ICP0 antibody (Figure 20A). Fluorescence microscopy analysis 
of all samples was performed during the same session and photographs were all taken at the same 
settings. Pixel density quantification revealed that ICP0 expression in single cells infected by Tet-in 
and Tet-inR was significantly higher than in those infected by the control viruses WT and ∆IR 
(approximately 2-fold > WT; 3-fold > ∆IR) (Figure 20B). The ICP0 level in cells infected by 
Tet∆34.5 was also slightly higher than that measured in cells infected by ∆IR (Figure 20B), but this 
difference was not significant. Thus, our data at a single cell level confirm our biochemical results 
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that mutants containing a displacement in the TAATGARAT element (1.5 kb in the Tet-in mutant and 
350 bp in the Tet-inR mutant) exhibit increased ICP0 expression. 
 
Figure 20. Immunocytochemistry of Vero cells infected by wild type HSV-1 (WT), ∆IR and TetICP0 
mutants (Tet∆34.5, Tet-in and Tet-inR) at a multiplicity of infection (MOI) of 0.007 for 24 hours. 
A. Images show fixed cells stained with 4', 6-diamidino-2-phenylindole (DAPI, blue) and antibody specific for 
ICP0 (green). Each panel displays overview of an imaging field (left) and gallery (right) of representative 
individual infected cells showing ICP0 staining. Scale bar, 50 μm. 
B. Quantification of average ICP0 expression per cell. Histogram representing average values obtained from 
integrated pixel densities of ICP0 staining in selected positive cells for each mutant. Error bars represent the 
standard error from analysis of 10-15 immunofluorescent positive cells for each virus. Asterisks indicate 
statistically significant (Student’s two-tailed t-test) increase in ICP0 expression compared to ∆IR (** P < 
0.0007) while the hash symbol indicates a significant increase compared to the WT (# P < 0.02). 
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5.10. Translocation of ICP0 in the Tet-in mutant occurs earlier 
Another aspect of ICP0 with important functional implications is its intracellular localization. 
In Vero cells infected by WT virus, newly synthesized ICP0 is principally nuclear where it colocalizes 
with PML and other ND10 components (Everett & Maul, 1994). Between 5 and 9 hours after 
infection, ND10 bodies are disrupted and ICP0 is translocated from the nucleus and dispersed in the 
cytoplasm (Lopez et al, 2001). Since proteasome-dependent degradation of ICP0 has been reported to 
occur principally in the nucleus (Gu et al, 2009), the high level of ICP0 in cells infected by the Tet-in 
mutant were examined to find if it might be due to a lower degradation rate because of a more 
cytoplasmic localization. Vero cells were infected with WT virus, and the Tet∆34.5, Tet-in and Tet-
inR mutants at an MOI of 1 and immunostained with anti-ICP0 and anti-PML antibodies at 4, 8 and 
24 hours post infection (Figure 21). 
 
Figure 21. Immunocytochemistry of Vero cells infected by wild type HSV-1 (WT), and TetICP0 mutants 
at a multiplicity of infection (MOI) of 1 for 4, 8 and 24 hours. 
Images show fixed cells stained with antibodies specific for PML (red) and ICP0 (green), and the merge of the 
red and green channels to visualize colocalization of PML and ICP0. Scale bar, 50 μm. 
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At 4 hours post infection, cells infected by all viruses exhibited nuclear ICP0 staining that co-
localized with PML bodies. At 8 hours post infection, all cells expressing ICP0 exhibited non-
punctate PML staining, indicating disruption of ND10 bodies. Mixed nuclear and cytoplasmic ICP0 
staining was observed in cells infected by WT virus or the Tet∆34.5 mutant whereas only cytoplasmic 
ICP0 staining was observed in cells infected by the Tet-in and Tet-inR mutants. At 24 hours post 
infection, cells infected by all viruses show completely cytoplasmic ICP0 staining (Figure 21). Thus, 
ICP0 in cells infected by Tet-in and Tet-inR translocates to the cytoplasm earlier than in cells infected 
by WT virus. Additionally, in the case of Tet-in, the protein aggregated in vesicle-like structures in 
the cytoplasm which could even be observed in lower amounts in cells at 4 and 8 hours post-infection 
(Figure 21). 
5.11. Qualitative and quantitative differences of ICP0 transcription in the Tet-in 
mutant 
To better understand the more direct effects of the modifications introduced in the Tet-in 
mutant we next studied ICP0 mRNA levels in Vero cells infected by Tet-in at an MOI of 1 compared 
to those infected by WT and ∆IR virus. Total RNA was prepared from cells 8 and 24 hours post 
infection and RT-PCR was used for semi-quantitative analysis of ICP0 transcripts (Figure 22). Since 
the inserted tetO cassette contains a minimal CMV promoter which might play a role in increasing 
ICP0 expression, oligonucleotides were used to detect transcripts originating at both the CMV start 
site as well as the ICP0 start site. As expected, ICP0 mRNA expressed by WT virus or the ∆IR mutant 
was derived only from the ICP0 start site (Figure 22A) whereas that expressed by the Tet-in mutant 
also consisted of a subset originating from the CMV start site (Figure 22A, middle row, rightmost 
two lanes). Densitometric quantification of triplicate experiments revealed that ICP0 mRNA levels of 
WT virus and the ∆IR mutant were similar whereas that of the Tet-in mutant was almost twice as high 
at 8 hours post-infection, but not significantly higher at 24 hours (Figure 22B). Transcription from the 
CMV start site in the Tet-in mutant showed a significant change from 8 to 24 hours (Figure 22B 
second panel) and although the proportion of these transcripts out of the total ICP0 mRNA cannot be 
accurately measured by our RT-PCR method, it can be seen that the kinetics of total ICP0 
transcription (Figure 22B first panel, compare Tet-in to WT) is perturbed by the extra activity from 
the CMV start site. ICP4 mRNA levels were also analzed in this experiment (Figure 22A and 22B 
third panel) which exhibited similar kinetics to the ICP0 samples, most likely reflecting the role of 
ICP0 as a transactivator of IE genes. 
Results 
77 
 
Figure 22. Semi-quantitative RT-PCR 
analysis of ICP0 mRNA expression by the 
Tet-in mutant. 
Vero cells were infected with the wild type 
HSV-1 (WT), and the ∆IR and Tet-in mutants at 
a multiplicity of infection (MOI) of 1 and 
harvested after 8 or 24 hours for total RNA 
isolation. 
A. Representative images of agarose gel 
electrophoresis of RT-PCR products using 
oligonucleotides specific for ICP0 transcripts 
originating either from the native ICP0 start site 
(top row, ICP0-S) or the cytomegalovirus 
(CMV) immediate-early minimal promoter start 
site (middle row, CMV-S), or ICP4 transcripts 
(bottom row). 
B. Histograms representing relative transcript 
levels derived by densitometry of the 
electrophoretic bands shown in A. Mean values 
from three independent experiments are shown, 
with error bars representing the standard error. 
Asterisks indicate statistically significant 
(Student’s two-tailed t-test) increases in 
expression at 24 hours with respect to the 8 hour 
value for the same virus (** P <0.005; * P < 
0.05) while the hash symbol indicates a 
significant difference in the Tet-in sample at 8 
hours compared to the WT or the ∆IR controls at 
8 hours (# P < 0.05). 
 
 
 
5.12. Tet-in and Tet-inR mutants exhibit reduced initial levels of ICP0 
The results described above indicate that ICP0 mRNA and protein levels were higher in cells 
infected by the Tet-in mutant than those infected by WT virus were puzzling in view of the fact that 
the modification in this mutant would be expected to weaken VP16 transactivation of ICP0 due to the 
1.5 kb displacement of the TAATGARAT motif away from the promoter. The present study 
hypothesized that all of the measurements might reflect delayed events in ICP0 expression kinetics 
and that perhaps reduced VP16 transactivation might only be directly observable during the 
immediate-early phase of infection. Thus, an established procedure using chemical inhibitors was next 
employed to examine HSV-1 gene expression corresponding to immediate-early (IE), early (E) and 
late (L) phases (Figure 23 and 24). Vero cells infected by the test viruses were incubated with 
cycloheximide for 6 hours to inhibit de novo translation, permitting only IE viral mRNA to 
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accumulate. The cells were then released from the translation block by changing into fresh medium 
containing: (1) the transcriptional inhibitor actinomycin D (Reich et al, 1961), allowing only the 
expression of viral IE genes; (2) the DNA synthesis inhibitor acyclovir (Harmenberg & Wahren, 
1982), allowing the expression of IE and E, but not L genes; no inhibitor, in which case viral genes of 
all 3 kinetic classes are expressed (Figure 23A). 
 
Figure 23. Analysis of ICP0 protein expression kinetics in Tet-in and Tet-inR mutants using 
pharmacological inhibitors. 
A. Schematic representation of the experimental set up. Vero cells were inoculated with the wild type HSV-1 
(WT), Tet-in and Tet-inR mutants at a multiplicity of infection (MOI) of 5, treated with cycloheximide 0.5 
hours before, to 6 hours after infection, and released thereafter into medium containing actinomycin D, 
acyclovir, or vehicle only. Total protein was extracted from the cells at 4 hours after release from cycloheximide 
and analyzed by western blot. 
B. Representative image of western blot using an ICP0-specific antibody showing detectable levels of the 66 
kDa cleavage product of ICP0 in WT and Tet-inR samples. No ICP0 protein expression was detectable in cells 
infected with the Tet-in mutant nor was full-length ICP0 detectable in any of the samples even at long 
exposures. 
 
Western blots of protein extracts made from cells 1 and 4 hours after the release from 
cycloheximide treatment revealed very low levels of ICP0; only the 66 kDa fragment could be 
detected at 4 hours, and only after long exposure times (Figure 23B). Thus RT-PCR was used to 
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analyse total RNA prepared from the same cells since the sensitivity of this assay is higher. As can be 
seen from Figure 24A, ICP0 expression levels of the Tet-in mutant are reduced in the IE and E phases 
(Figure 24B, asterisks indicate significant decrease of Tet-in samples treated with actinomycinD or 
acyclovir compared to WT samples treated with the same drugs), and as expected, are restored 
towards WT levels in the Tet-inR mutant (Figure 24B, cross-hatch indicates significant increase of 
vehicle-treated Tet-inR samples compared to vehicle-treated Tet-in samples). ICP0 levels in vehicle-
treated Tet-inR samples at 1 hour treatment appeared higher than vehicle-treated WT samples (Figure 
24B, difference not statistically significant), possibly due to the activity of the CMV promoter. 
 
Figure 24. Analysis of ICP0 expression kinetics in Tet-in and Tet-inR mutants using pharmacological 
inhibitors. 
A. Vero cells were inoculated with the wild type HSV-1 (WT), Tet-in and Tet-inR mutants at multiplicity of 
infection (MOI) 5, treated with cycloheximide 0.5 hours before, to 6 hours after infection, and released 
thereafter into medium containing actinomycin D, acyclovir, or vehicle only. Total RNA was extracted from the 
cells at 1 and 4 hours after release from cycloheximide and analyzed by RT-PCR. Representative image of 
agarose gel electrophoresis of RT-PCR products using oligonucleotides specific for ICP0 transcripts originating 
from the native ICP0 start site is shown. 
B. Histograms representing relative transcript levels derived by densitometry of the electrophoretic bands shown 
in B. Mean values from three independent experiments are shown, with error bars representing the standard 
error. Asterisks indicate statistically significant (Student’s two-tailed t-test) differences in expression with 
respect to the WT value (* P < 0.05) while the hash symbol indicates a significant difference in the Tet-in 
sample compared to the corresponding Tet-inR sample (# P < 0.02). 
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Thus, these data confirm that the modification of the TAATGARAT site in the ICP0 promoter 
in the Tet-in mutant diminishes initial ICP0 levels but that this later leads to overexpression due to the 
characteristics of ICP0 regulatory circuitry. 
5.13. Binding of the tetR-KRAB fusion protein to the modified ICP0 promoter 
reduces Tet-in growth 
To investigate the effect of tetR-KRAB-mediated repression on Tet-in replication via the tetO 
sites inserted in the ICP0 promoter, viral titers were analyzed in Vero and tetR-KRAB expressing 
Vero (Vero-tetRKRAB) cell lines infected at an MOI of 0.1 for 24 hours. Figure 25A shows that in 
Vero-tetRKRAB cells, the titer of the Tet-in mutant was significantly lower than that observed in 
Vero cells (down to approximately 25%), indicating that binding of tetR-KRAB to the inserted tetO 
sites can mediate growth repression, although not completely. Curiously, no effect on viral titer was 
observed in response to doxycycline. In the next experiment the effect of tetR-KRAB mediated 
repression was analyzed on ICP0 protein expression level in Vero and Vero-tetRKRAB cell lines 
infected with Tet-in mutant at an MOI of 0.1. 
Figure 25. Effect of the tetracycline 
repressor / Krüppel-associated box domain 
(tetR-KRAB) fusion protein on the tetO 
sites inserted in the Tet-in mutant. 
A. The viral titer of the Tet-in mutant at 24 
hours after infection at a multiplicity of 
infection (MOI) of 0.1 in Vero, or Vero cells 
expressing tetR-KRAB protein (Vero-
tetRKRAB) in the absence of doxycycline (-
Dox) or in the presence of doxycycline 
(+Dox). The histogram represents mean 
values of three independent experiments. 
Error bars indicate standard errors. 
Statistically significant decreases (Student’s 
two-tailed t-test) in Tet-in mutant titer 
obtained in Vero-tetRKRAB compared to the 
Vero cells are indicated by asterisks (** P < 
0.006). 
B. Western blot of lysates made from Vero 
cells or Vero-tetRKRAB cells after infection 
by the Tet-in mutant at a multiplicity of 
infection (MOI) of 0.1 for 24 hours. ICP0 
polypeptides were detected in infected cells, 
including full-length (110 kDa) ICP0, and the major cleavage product of 66 kDa. 
C and D. Histograms representing the relative protein quantity of the 110 kDa species (C) and the 66 kDa 
cleavage product (D) derived by densitometry of the electrophoretic bands shown in B, expressed as a 
percentage of the total protein quantified. Mean values from three independent experiments are shown, with 
error bars representing the standard error. No repressive effect of the tetR-KRAB fusion protein was observed 
on full length ICP0 product (110 kDa); levels of the 66 kDa band were lower in Vero-tetRKRAB cells although 
this difference was not statistically significant (P = 0.19). 
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Densitometric analysis of ICP0 bands observed in western blots with lysate derived from the 
two infected cell lines revealed almost negligible effect of tetR-KRAB on full length ICP0 band (110 
kDa) (Figure 25B and 25C). However, a reduced level of the 66 kDa band was observed in Vero-tetR 
KRAB cells (down to approximately 64% of expression in Vero) which decreased further in presence 
of doxycycline (down to approximately 45% of expression in Vero) (Figure 25B and 25D), although 
this difference was not statistically significant. 
Taken together, these results (Figure 25) indicate that tetR-KRAB mediates repressive 
activity in the Tet-in mutant. However, this effect was incomplete and neither ICP0 expression nor 
mutant growth was repressed completely. These observations suggest the presence of interference in 
the system which influences tetO-mediated transcriptional control. As a cautionary note, in these 
experiments data for control virus (WT or ∆IR) are missing, and thus it is not completely clear if the 
observed effect is specific to tetR-KRAB and not due to variation between a cell lines. 
5.14. ICP0 influences tetracycline-regulated transgene expression and elevates 
basal transcription from the tetracycline-regulated promoter 
To investigate the possibility of interference of HSV-1 IE proteins on tetracycline-mediated 
transgene regulation, a set of assays using luciferase reporters was designed. A reporter plasmid, 
pUHC13-3 (Gossen & Bujard, 1992), encoding the Photinus pyralis luciferase gene regulated by 7 
tetO elements juxtaposed to the cytomegalovirus (CMV) minimal promoter was cotransfected in Vero 
cells with plasmids expressing tetR-KRAB fusion protein (pLVPRT-tTRKRAB, (Szulc et al, 2006)) 
and ICP0 (pAXKS) or ICP4 (p175, (Perry et al, 1986)). Plasmid pBluescript II (Alting-Mees & Short, 
1989) was used as control nonspecific DNA in all experiments to normalize the total DNA load in 
each combination of transfection. 
Luciferase assays performed at 24 hours post transfection displayed significant doxycycline-
responsive repression of tetR-KRAB on tetO regulated luciferase expression, which is perturbed in 
the presence of the HSV-1 IE proteins ICP0 or ICP4 (Figure 26A). The results in this experiment can 
be summarized as follows: (1) the presence of ICP0 and ICP4 significantly elevates the basal level of 
luciferase up to 6-fold; (2) interference of ICP0 is greater than that of ICP4; (3) the interference by 
ICP4 does not completely abolish inducibility and occurs only in the absence of tetR-KRAB; (4) ICP0 
produces interference both in the presence and in the absence of tetR-KRAB and (5) the interference 
was significantly higher in the presence of doxycycline (Figure 26A). 
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Figure 26. ICP0 interferes with tetracycline-regulated transgene expression. 
A. Luciferase expression after co-transfection of a plasmid encoding a tetracycline-regulated luciferase reporter 
(pUHHC13-3) with plasmids expressing ICP0 or ICP4 and the tetR-KRAB fusion protein. To maintain the total 
amount of transfected DNA constant in all samples, the plasmid pBluescript II was used as non specific filler 
DNA (FD). Luciferase activity in the presence (+Dox) and in the absence (-Dox) of doxycycline was determined 
24 hours after transfection and represented as relative light units (RLU). Mean values from three independent 
experiments are shown, with error bars representing the standard error. Asterisks indicate statistically significant 
(Student’s two-tailed t-test) differences in expression due to the effect of doxycycline (Dox) (* P < 0.05, ** P < 
0.005) while the hash symbol indicates a significant difference in the value compared to the corresponding 
control without ICP0 or ICP4 (# P < 0.05). 
B. Plasmid encoding a tetracycline-regulated luciferase reporter (pUHC13-3) was co-transfected with plasmids 
expressing ICP0 and the tetracycline-responsive regulators: tTA or rtTA or tetR-KRAB. Plasmid pBluescript II 
was used as control nonspecific filler DNA (FD) to maintain the total amount of transfected DNA constant in all 
samples. Luciferase activity in the presence (+Dox) and in the absence (-Dox) of doxycycline was determined 
24 hours after transfection. Histogram represents fold increase in the luciferase expression level in ON state over 
OFF state. Mean values from three independent experiments are shown, with error bars representing the 
standard error. 
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These data indicate that expression of the HSV-1 IE genes ICP4 and ICP0 elevates basal 
transcription of the tetO regulated transgene. ICP4 is known to induce transcription by forming a 
complex with TATA binding protein and transcriptional factor TFIIB (Cheung et al, 1997; Homa et 
al, 1988). The KRAB domain on the other hand is a DNA binding dependent transcriptional repressor 
(Margolin et al, 1994) which when tethered to DNA creates a local heterochromatin state extending 
over a region with a radius of 2-3 kb (Moosmann et al, 1997; Senatore et al, 1999). Binding of the 
tetR-KRAB protein to the tetO sites hinders RNA polymerase II- mediated transcription and impedes 
ICP4-mediated transactivation; as observed by a decrease in the interference in the presence of tetR-
KRAB. ICP0 also induces transcriptional activation and markedly enhances basal transgene 
expression. Since, ICP0 has been known to unwind and open up chromatin to increase accessibility to 
transcriptional machinery (reviewed in (Hagglund & Roizman, 2004)), this could explain why the 
presence of ICP0 antagonizes tetR-KRAB-mediated functions. 
Finally, it was investigated if ICP0 also interferes with the activity of the Tet transactivator 
proteins- tTA and rtTA. Luciferase assays were performed on the lysates obtained from co-
transfection of a plasmid bearing a Tet-regulated transgene reporter (pUHC13-3) with ICP0 and Tet-
regulator expressing plasmids (tTA; pUG6SP-tTA or rtTA; pLD-puro-2A-rtTA-TcVA). The values 
obtained in the assay indicate that tTA and rtTA binding at the tetO sites respectively induce 33- and 
38-fold increases in luciferase levels which reduce down to 11- and 7-fold in the presence of ICP0 due 
to an increase in the baseline luciferase expression level (Figure 26B). These results indicate that 
ICP0 not only interferes with tetR-KRAB-mediated transcriptional repression but also affects tTA and 
rtTA-mediated transcriptional activation. However, the ICP0-mediated interference on tetR-KRAB is 
larger than the other tested Tet regulators. In the absence of ICP0, tetR-KRAB represses transgene 
expression up to 28-fold which reduces approximately to 3-fold in the presence of ICP0 (Figure 
26B). 
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6. DISCUSSION 
Herpesvirus genomes contain direct or inverted repeats (IR), the reasons for which are not 
clearly understood. In HSV-1 the duplicated components in the IR and TR sequences include three 
genes: ICP4, ICP0 and ICP34.5. The present study generated the ∆IR mutant using BAC technology 
with the aim of creating a completely haploid HSV-1 genome to facilitate further genetic engineering. 
The characterization of ∆IR mutant confirms previous results that IR deletion does not significantly 
affect viral titer in culture on permissive cells (Brown et al, 1984; Jenkins et al, 1996; Poffenberger et 
al, 1983) even though there appears to be a slight delay at early time points and in the absence of 
virion components. Nevertheless, although the double dosage of genes found in IR is not directly 
necessary for lytic replication, in vivo studies have revealed that it is important for HSV-1 
pathogenicity (Jenkins et al, 1996; Jenkins & Martin, 1990; Junejo & Brown, 1995), indicating a role 
in modulation of virus-host interactions. On par with this finding IR deletion studies in other 
Herpesviruses e.g Equine Herpes Virus-1 (EHV-1) and HCMV have demonstrated no significant 
effect on viral titer in vitro (Ahn et al, 2011; Sauer et al, 2010). However, reduced virulence in vivo 
and lack of genomic isomerisation have been observed to result (Ahn et al, 2011; Sauer et al, 2010). 
6.1. A ∆IR mutant deleted in the ICP34.5 gene and mutated in the ICP0 
promoter is deficient in replication 
In vitro characterization of mutants constructed over ∆IR backbone reveals that viral 
replication is severely affected when the remaining copy of the ICP34.5 gene along with the 
TAATGARAT elements of the ICP0 promoter is deleted from the ∆IR genome (Tet∆34.5TG mutant). 
In contrast, replication of the ∆IR genome was not eliminated in separate mutants with deletions 
either in the ICP34.5 gene (Tet∆34.5 mutant), the consensus TAATGARAT element (Tet∆TG 
mutant), or in the ICP0 promoter (Tet-in mutant), but combining all modifications resulted in a 
nonproductive genome (Tet∆34.5TG mutant) which was also severely affected in amplicon packaging 
ability (Figure 12). The Tet∆34.5TG mutant failed to yield measurable viral titers even when 
transfected into reverse tetracycline responsive transactivator (rtTA) expressing Vero (Vero-rtTA) 
cells or in human osteosarcoma U2OS cells which are known to support the growth of ICP0 null 
mutants (Yao & Schaffer, 1995). This suggests that in the absence of ICP34.5, ICP0 executes an 
essential function which is not either compensated by expression using the tetracycline-regulated 
transactivation system or complemented by the U2OS cell line. The results from the present study are 
consistent with earlier findings which demonstrate that although deletion mutants of ICP0 and 
ICP34.5 are viable in permissive cell lines, they are hypersensitive to host antiviral IFNs (Chou & 
Roizman, 1992; Mossman et al, 2000) and the two proteins counteract distinct interferon (IFN) 
barriers to viral transcription and translation (Mossman & Smiley, 2002). Supporting this finding, our 
∆IR mutant deleted in the ICP34.5 gene (Tet∆34.5 mutant) displays a moderate reduction in viral titer 
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compared to WT at high MOI but this defect was greater at low MOI (Figure 16) indicating that the 
importance of ICP34.5 in viral replication is MOI dependent; at low MOI the synergistic actions of 
ICP34.5 and ICP0 to target host immune responses are required for productive infection. 
The study demonstrates that the inability of the Tet∆34.5TG mutant to produce infectious 
virions can be overcome by reconstituting the ICP22 promoter and providing an extra origin of 
replication (Tet∆34.5TG-K; Figure 13). However, a subsequent experiment with a mutant carrying an 
additional oriS ectopically (Tet∆34.5TG-O; Figure 14) indicates that reconstitution of the ICP22 
promoter has a more important role in complementation of Tet∆34.5TG replication than providing an 
extra origin of replication (oriS). ICP22 has been previously reported as a critical HSV-1 regulatory 
factor with roles in alteration of RNA polymerase II, modification of cell cycle components like cdk1, 
formation of virus-induced chaperone-enriched domains (VICE) and relocalization of host chaperones 
e.g. Hsc70 (reviewed in (Rice & Davido, 2013)). Despite the fact that ICP22 null
 
mutants replicate 
efficiently in permissive but not in restrictive cell lines (Poffenberger et al, 1993; Post & Roizman, 
1981), it is currently unclear if ICP22 provides any replicative advantage to the virus. One possibility 
that has been postulated is that ICP22 functions to inhibit antiviral responses and suppresses host gene 
transcription rather than inducing viral gene expression. Supporting this, earlier studies have shown 
that several RNA viruses evade the type I interferon system by altering phosphorylation of RNA 
polymerase II (Thomas et al, 2004; Verbruggen et al, 2011). However, further studies will be required 
to determine if, in fact, the antiviral response of ICP22 is an important component of its 
complementation of replication of the Tet∆34.5TG mutant. 
Failure of the Tet∆34.5TG mutant in establishing productive infection in spite of expressing 
IE (ICP0) and L (gC) HSV-1 proteins (Figure 15) indicates two points: (1) mere expression of ICP0 
is insufficient and correct kinetics of ICP0 processing (nucleus-cytoplasm translocation, proteolytic 
cleavage) is critical in terms of viral replication; and (2) inhibition of viral growth occurs after 
completion of L gene expression. 
6.2. Distal displacement of the TAATGARAT element from the transcription 
start site (TSS) leads to overexpression and aberrant processing of ICP0 
The present study yielded further insight regarding the dependence of viral replication on 
ICP0 expression by analysis of the curious properties of Tet-in mutant, a ∆IR-derived virus with an 
insertion of 7 tetO repeats, displacing the natural TAATGARAT element 1.5 kb away from the TSS. 
As predicted, viral replication was significantly reduced in this mutant, consistent with the known 
importance of ICP0 transactivation by VP16 via the TAATGARAT element (reviewed in (Wysocka 
& Herr, 2003)). However, contrary to expected, western blots revealed an immense overexpression of 
ICP0 (Figure 18). This result was puzzling but support that this was not a technical artifact came 
from analysis of the Tet-inR mutant, in which I reduced the TAATGARAT displacement from the 
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TSS from 1.5 kb to 350 bases by deletion of the RP-Kan
R
 cassette. Relative to the Tet-in mutant, viral 
replication was improved and ICP0 overexpression was decreased in the Tet-inR mutant and it 
behaved in a manner intermediate between Tet-in and WT with respect to both viral replication and 
ICP0 expression (Figure 17 and 18). Quantification of ICP0 expression in single infected cells 
showed significant elevation in ICP0 level in Tet-in and Tet-inR mutants compared to the control 
viruses (WT, ∆IR) (Figure 20). This result verifies that the observed overexpression of ICP0 in 
TAATGARAT displaced mutants was specifically due to the mutation in the promoter element and 
not due to possible differences in titer measurements of ICP0 mutants compared to control viruses. As 
shown in previous studies, ICP0 undergoes proteolytic cleavage during early times into several 
discrete polypeptides which subsequently degrade in a proteasome dependent pathway (Gu et al, 
2009). Western blot performed at different times of infection revealed that ICP0 protein levels in the 
Tet-in and Tet-inR mutants are not only abnormally elevated but also possess altered kinetics for ICP0 
cleavage and degradation (Figure 19). Additionally, faster cytoplasmic translocation of ICP0 was 
observed in Tet-in infected cells which further increases at late times (Figure 21). Curiously, a similar 
phenotype was observed earlier with an ICP4 deletion mutant (d120) (Lopez et al, 2001). As ICP0 has 
roles in transactivation of other HSV-1 IE genes (Cai & Schaffer, 1992), this study indicates that an 
alteration in the kinetics of its levels might have pivotal effects on the expression of other IE genes. 
Since the dramatic overexpression of ICP0 was the complete opposite of what might be 
expected by weakening VP16 transactivation, the study postulated that the western blots of ICP0 
expression in our study may not detect IE events because protein extracts were made after multiple 
cycles of non-synchronized viral infection, when dynamic changes in ICP0 expression levels during 
the course of many single viral replication cycles may mask differences in initial ICP0 levels which 
would best reflect the direct effects of TAATGARAT displacement in the ICP0 promoter. This was 
indeed confirmed by the cycloheximide reversal experiment which revealed that IE levels of ICP0 are 
lower in the Tet-in and Tet-inR mutants compared to WT (Figure 24). 
The results are consistent with the idea that within the ICP0 promoter, the TAATGARAT 
element not only mediates IE transactivation, but also forms part of a dynamic control circuit with an 
inhibitor which normally performs feedback regulation of initial increases in ICP0 expression. Thus, 
displacement of the TAATGARAT site in the Tet-in mutant results in decreased, and/or delayed 
inhibition, resulting in an overall (late) augmented level of ICP0 expression. Consistent with this, the 
TAATGARAT motif has been found to confer both positive and negative responses to cellular factors 
(Thomas et al, 1998). 
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6.3. TetO sites inserted in ICP0 promoter cannot substitute for the full activity 
mediated by the TAATGARAT element 
Although growth of the Tet-in mutant observed improved in rtTA expressing Vero cells, viral 
titer was still well below WT levels, indicating that the artificial tethering of the VP16 transactivation 
domain to the ICP0 promoter is not sufficient to reproduce the full activation mediated via the 
TAATGARAT element. One possibility is that other transcription factors are necessary; even though 
it has been reported that only a small region of VP16 is necessary for complex formation with HCF 
and Oct-1 (Lai & Herr, 1997), these interactions may be suboptimal with the rtTA chimeric protein. 
Indeed, interaction with a factor binding to the GC-rich region immediately upstream of the 
TAATGARAT site in the ICP0 promoter is known to modify transactivation (Kwun & Jang, 2000). A 
second possibility is that the distance between the TAATGARAT element and the TSS is critical – 
this is directly indicated by observation that reducing the TAATGARAT displacement in the Tet-inR 
mutant increased IE transactivation and improved replication, and supported by other work showing 
that VP16 complexed to HCF and Oct-1 transactivates through TAATGARAT elements only from 
promoter-proximal positions (Hagmann et al, 1997). Finally, the continuous binding of rtTA to the 
inserted tetO elements most probably results in transactivation kinetics quite different to that produced 
by VP16 interaction with the ICP0 promoter during normal viral infection. The above possibilities are 
not mutually exclusive, and may all contribute to the altered replication of the Tet-in and Tet-inR 
mutants. 
Surprisingly, in rtTA cells, doxycycline did not modify viral replication of any of the tetO-
containing mutants (Tet∆34.5, Tet-in or Tet-inR), or produce statistically significant changes in ICP0 
protein expression by Tet-in or Tet-inR detectable by western blots. This was not due to anomalies in 
the tetO cassette since: (1) the tetO repeats were checked by sequencing the BACs encoding these 
mutants; (2) as mentioned above, increased replication of the tetO-containing mutants was observed 
in rtTA-expressing cells; (3) in the Tet∆34.5 mutant, although doxycycline did not affect viral 
replication, in western blots, full-length ICP0 protein levels appeared consistently higher in rtTA cells 
treated with doxycycline (Figure 18A), although this difference was not statistically significant. Since 
ICP0 is known to act as a promiscuous transactivator by rendering DNA more accessible to 
transcription factors (Kalamvoki & Roizman, 2010), an explanation for the insensitivity of ICP0 
mutants to doxycycline in rtTA cell line is that in the presence of sufficient levels of ICP0, the basal 
affinity of rtTA for tetO sites is augmented to such an extent that doxycycline does not further 
augment binding significantly. 
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6.4. ICP0 interferes with the tetracycline repressor-KRAB (tetR-KRAB)-
mediated silencing of tetO-controlled gene transcription 
Similar to Vero-rtTA cells, Vero cells expressing tetR-KRAB (Vero-tetRKRAB) did not 
modify the replication of the Tet-in mutant in response to doxycycline. However, a significant 
difference between the Tet-in titers obtained in Vero and Vero-tetRKRAB confirms that KRAB 
repressor activity was mediated by the tetO sites inserted in the mutant. Since in this set of 
experiment, data for control virus (WT or ∆IR) was missing, it cannot be concluded definitively that 
the decrease in Tet-in mutant titer in Vero-tetRKRAB cells compared to Vero cell line was 
exclusively due to the transcriptional repression mediated by KRAB protein and was not due to 
variation between the two cell lines. The Vero-tetRKRAB cell line used in the experiment was 
generated by clonal selection and was checked functionally by luciferase assay using a reporter 
plasmid (data not shown). In view of the fact that the Vero-tetRKRAB cell line displays inducible 
transcriptional repression of tetO inserted reported gene, the present study suggests that the observed 
difference in viral titer was specific to the presence of tetRKRAB and not due to variation between the 
two cell lines, although further experiments would be needed to confirm this. 
These results suggest insufficient difference between the ON and OFF state of the 
tetracycline-regulated switch in our system. Although several HSV-1 derived vectors incorporating 
tetracycline-regulated switches have been generated (Ho et al, 1996; Schmeisser et al, 2002; Yao et al, 
2010; Yao et al, 1998; Yao et al, 2006) some studies indicate that HSV-1 gene products, particularly 
ICP4, can interfere with the performance of tetracycline-regulated systems (Herrlinger et al, 2000). 
Indeed, experiments with a reporter plasmid (pUHC13-3) in this thesis demonstrate an increase in 
basal escape of expression provoked by the presence of ICP0 and ICP4 (Figure 26A). ICP0-mediated 
interference on tetO controlled transcriptional regulation was observed in presence of Tet regulator 
proteins- tTA, rtTA but maximum interference was observed with tetR-KRAB (Figure 26B). The 
KRAB repressor has been reported to function by closing up chromatin structure (Moosmann et al, 
1997; Senatore et al, 1999; Wiznerowicz & Trono, 2003) whereas ICP0 has been found to unwind and 
open up chromatin to increase accessibility to transcriptional machinery (reviewed in (Hagglund & 
Roizman, 2004)). This study argues that ICP0 antagonizes KRAB-dependent silencing of tetO-
mediated transcription leading to the collapse of the regulatory system. 
6.5. Regulation of ICP0 expression in HSV-1 infected cells 
ICP0 expression is known to be controlled both by an autostimulatory feed-forward loop as 
well as an inhibitory feedback loop (Faber & Wilcox, 1986; Lium et al, 1996). Previous studies have 
indicated that ICP0 is regulated differently by at least three viral proteins i.e. VP16, ICP4 and ICP0 
(Liu et al, 2010). These findings suggest that: (1) VP16 transactivates both the ICP0 and ICP4 genes; 
(2) ICP0 transactivates other IE, E and L genes; (3) ICP4 silences ICP0 transcription when ICP0 fails 
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to accumulate, and (4) ICP0 itself acts as an inhibitor of ICP4-mediated transcriptional repression of 
HSV-1 genes, including that of ICP0 itself (Liu et al, 2010) (Figure 27). 
 
Figure 27. Schematic representation of ICP0 regulatory interactions. 
Virion protein 16 (VP16) is a HSV-1 virion protein which induces transcription of immediate early (IE) 
genes: infected cell protein (ICP) 0 and ICP4. ICP0 transactivates ICP4, as well as its own transcription. When 
ICP0 fails to accumulate, ICP4 inhibits ICP0 mRNA synthesis but when ICP0 is present it antagonizes ICP4-
mediated repression of ICP0. ICP0 also induces late protein VP16 translation. In the present study VP16 
mediated transcriptional activation of ICP0 has been interrupted (represented as black double lines). 
 
In the present study I have attempted to substitute the natural VP16-mediated transactivation 
of ICP0 with an artificial tetracycline-regulated system to analyze the dependence of viral replication 
on ICP0 transcription. The results of this thesis support the role of ICP0 as a critical switch 
component in HSV-1 productive infection, but also indicate that attempts to impose control over ICP0 
expression may not necessarily translate into changes in viral replication. The study concludes that the 
maintenance of correct ICP0 kinetics is more critical for viral replication than simply switching the 
expression of the ICP0 gene ON or OFF. Here, the term “kinetics” refers to dynamic changes in 
protein expression and processing. ICP0 is a multifunctional polyprotein with complex kinetics, 
entailing proteolytic cleavage and nuclear to cytoplasmic translocation (Gu et al, 2009; Lopez et al, 
2001). The TAATGARAT displacement in Tet-in mutant alters ICP0 kinetics resulting in high levels 
of ICP0 and faster translocation of the protein to the cytoplasm, all of which result in reduced viral 
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yield. These results indicate that high levels of ICP0 do not necessarily assure viral growth and may 
even be detrimental when expression kinetics are altered Additionally, it can also be concluded that 
the distance between the TAATGARAT element and the transcription start site of ICP0 promoter is 
critical. The TAATGARAT element imposes complex dynamic control on ICP0 transcription by 
mediating not only stimulatory but also inhibitory effects on the promoter. These effects cannot be 
reproduced by simple tethering of VP16 to the promoter such as with the tetracycline-responsive 
system. The transcriptional control of ICP0 may not necessarily translate into changes in viral 
replication since regulatory feedback mechanisms downstream of ICP0 expression may counteract 
these changes. Taken together, this would suggest that ICP0 control could more easily be achieved 
either upstream of the TAATGARAT element, possibly by modifying VP16/Oct-1/HCF complex 
formation, or at downstream events affecting ICP0 accumulation. Supporting this hypothesis, a recent 
in vivo study has reported that a VP16 mutant virus is incapable of exiting latency (Thompson et al, 
2009). On the other hand, an important question will be to determine if wild-type viral titers can be 
attained by restoring VIC formation or normal ICP0 accumulation. 
Many of the HSV-1 genes encoded during lytic replication serve dual functions: (1) assisting 
in viral replication and (2) counteracting innate or adaptive immune responses. ICP0 and ICP34.5 are 
particularly important in this regard as they assist in viral replication and target type-1 IFN pathways 
to circumvent host immune responses ((Mossman & Smiley, 2002), reviewed in (Lanfranca et al, 
2014)). ICP34.5 bridges protein phosphatase 1 (PP1) and translation initiation factor (eIF2) via their 
binding motifs and thereby facilitates the protein synthesis and viral replication (Li et al, 2011). ICP0 
is a promiscuous transactivator of viral genes and enhances viral replication both in vitro and in vivo 
(Cai & Schaffer, 1989; Everett, 1984; Everett, 1985; Gelman & Silverstein, 1985; Harris et al, 1989; 
Kalamvoki & Roizman, 2010; Sacks & Schaffer, 1987). In addition, ICP0 disperses ND 10 bodies 
that are normally associated with transcriptional regulation, growth suppression, and apoptosis. In the 
present study, complete disruption of viral replication was observed when simultaneous mutations in 
ICP34.5 and ICP0 (Tet∆34.5TG mutant) were made, indicating that insufficient immunomodulatory 
activity leads to a block in replication. It will be interesting to test the reversibility of this effect by 
conditional expression of ICP34.5. In view of the role of ICP0 and ICP34.5 in counteraction of host 
immune responses, another informative line of research would be to characterize the phenotype of the 
mutant Tet∆34.5TG in an IFN-deficient cell line. 
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CONCLUSIONS 
1. The inverted repeat (IR) sequences of HSV-1 are dispensable for growth in vitro, 
indicating that a haploid HSV-1 genome is sufficient for viral replication. 
2. In the absence of ICP34.5, ICP0 becomes a critical determinant of replication in a 
haploid HSV-1 genome. 
3. The distance between the TAATGARAT element and the transcription start site of 
ICP0 promoter is critical. An increase in this distance alters ICP0 kinetics, decreasing 
immediate early expression, but increasing later accumulation of ICP0. 
4. Higher levels of ICP0 do not necessarily assure better viral growth and may even be 
detrimental when expression kinetics are altered. 
5. The TAATGARAT element of the ICP0 promoter imposes complex dynamic control 
on ICP0 expression by mediating both stimulatory and inhibitory effects on 
transcription. The artificial regulatory tetracycline-responsive system cannot substitute 
for the full activity mediated by the TAATGARAT element. 
6. ICP0 itself interferes with the tetracycline inducible system and therefore cannot be 
accurately controlled by this system. 
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CONCLUSIONES 
1. La secuencia de la repetición invertida del VHS-1 resulta dispensable para el 
crecimiento in vitro, indicando que un genoma haploide es suficiente para la replicación 
viral del VHS-1. 
2. En la ausencia de ICP34.5, ICP0 es un factor determinante en la replicación del VHS-1 
de genoma haploide. 
3. La distancia entre el elemento TAATGARAT y el sitio de inicio de la transcripción del 
promotor de ICP0 es importante. Un aumento en dicha distancia produce una alteración 
de la cinética de ICP0, disminuyendo la expresión inmediatamente temprana pero, por 
otro lado, incrementando la acumulación tardía de ICP0. 
4. El incremento de los niveles de ICP0 no se correlaciona con un mejor crecimiento viral, 
incluso pudiendo llegar a actuar en detrimento cuando la cinética de la expresión se 
haya alterada. 
5. El elemento TAATGARAT del promotor de ICP0 ejerce un complejo control dinámico 
en la expresión de ICP0 mediante la mediación entre los efectos estimulatorios así 
como inhibitorios de la transcripción. La completa actividad mediada por el elemento 
TAATGARAT  no puede ser sustituida por el sistema artificial regulatorio sensible a  
tetraciclina. 
6. La interferencia de ICP0 con el sistema inducible de tetraciclina impide la regulación 
de dicho gen mediante este sistema. 
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